[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112282
6. Laca L, Urdzik J, Dobrota FM, Polácek H: [Limitations of liver resections]. Rozhl Chir; 2009 Mar;88(3):127-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Limitations of liver resections].
  • Evaluation of the functional reserve before resectional performance and sufficient rest of liver parenchyma function is essential for the surgeon.
  • From these factors, the decision based on operability, the maximum extent of liver parenchyma resection and the severity of post-operative course.
  • In the period from December 2003 to December 2008, at the Dept of Transplant and Vascular surgery, JLF UK Martin, have been performed 161 resections of the liver in 144 patients, of which 91 large resections performances in the liver (hemihepatektomies or greater performance).
  • Of 91 major resection performance in the liver was 62 (68%) performed by anatomical boundaries of individual segments, in remaining 29 (32%) resections was reflected more to the localization of tumor itself as anatomical subdivision called combined anatomical and non-antomical resection.
  • Radical resection R0 has been achieved in 76% of malignant tumors.
  • In the post-operative course in 17% experienced complications, most often to the hematoma and biloma in place of the resection area, pleural effusion and 8 patients had postoperative liver dysfunction.
  • Of this group, 5 patients had made volumetric examinations, and in all was the volume of residual liver parenchyma < 30% of the total volume of functional liver.
  • The survival of patients was affected mainly by extent of resection, histological type of tumor, radicality of resection and necessity of the complex surgical procedures.
  • Based on our evaluation of the results of a group of patients was arranged scheme measures for planning resectional procedures of the liver in our department.
  • These include the adjustment of laboratory parameters, management of jaundice, preference of anatomical resections and volumetric examinations in patients with an estimated loss of more than 60-70% functional parenchyma of liver.
  • [MeSH-minor] Female. Humans. Liver / physiopathology. Male. Middle Aged. Postoperative Complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526944.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] slo
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


7. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V: Biomarkers of liver fibrosis. Adv Clin Chem; 2008;46:131-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biomarkers of liver fibrosis.
  • Liver biopsy, due to its limitations and risks, is an imperfect gold standard for assessing the severity of the most frequent chronic liver diseases.
  • This chapter summarized the advantages and the limits of the available biomarkers of liver fibrosis.
  • The mean diagnostic value for the diagnosis of advanced fibrosis assessed using standardized area under the receiver operating characteristics (ROC) curves was 0.84 [95% confidence interval (CI), 0.83-0.86], without significant difference between the causes of liver disease, hepatitis C, hepatitis B, alcoholic or nonalcoholic fatty liver disease.
  • Due to the evidence-based data, health authorities in some countries have already approved validated biomarkers as first-line procedure for the staging of liver fibrosis.
  • This overview of evidence-based data suggests that biomarkers could be used as an alternative to liver biopsy for the assessment of fibrosis stage in the four more common chronic liver diseases: C virus (HCV), hepatitis B virus (HBV), hepatitis nonalcoholic fatty liver disease (NAFLD), and alcoholic liver disease (ALD).
  • [MeSH-major] Liver Cirrhosis / diagnosis
  • [MeSH-minor] Biomarkers. Biopsy. Humans. Liver / pathology. Patents as Topic

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19004189.001).
  • [ISSN] 0065-2423
  • [Journal-full-title] Advances in clinical chemistry
  • [ISO-abbreviation] Adv Clin Chem
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 109
  •  go-up   go-down


8. Sadamori H, Yagi T, Iwagaki H, Matsuda H, Shinoura S, Umeda Y, Ohara N, Yanai H, Ogino T, Tanaka N: Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation. J Gastroenterol Hepatol; 2009 Apr;24(4):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical staining of liver grafts with a monoclonal antibody against HCV-Envelope 2 for recurrent hepatitis C after living donor liver transplantation.
  • AIM: We evaluated the expression of hepatitis C virus (HCV) antigen on liver grafts by immunohistochemical staining (IHS) using IG222 monoclonal antibody (mAb) against HCV-envelope 2 (E2).
  • METHODS: The study material was 84 liver biopsy specimens obtained from 28 patients who underwent living donor liver transplantation (LDLT) for HCV infection.
  • There was no significant correlation between the IHS grades using IG222 mAb and serum HCV-RNA levels when data of 84 liver biopsy specimens were analyzed.
  • CONCLUSIONS: Constant HCV-E2 expression was observed in liver biopsy specimens obtained 1 month or longer.
  • The strong HCV-E2 expression on liver grafts were associated with recurrent hepatitis C after LDLT, but the serum HCV-RNA levels were not.
  • [MeSH-major] Hepacivirus / isolation & purification. Hepatitis C / virology. Immunohistochemistry. Liver / virology. Liver Cirrhosis / surgery. Liver Transplantation. Living Donors. Viral Envelope Proteins / analysis


9. Wang WL, Zheng SS, Xu X, Liang TB, Jin J, Shen Y, Zhang M, Wu J: [Clinical evaluation of emergency liver transplantation for patients with benign end-stage liver diseases]. Zhonghua Yi Xue Za Zhi; 2005 Dec 28;85(49):3460-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of emergency liver transplantation for patients with benign end-stage liver diseases].
  • OBJECTIVE: To evaluate the efficacy of emergency liver transplantation in treating patients with benign end-stage liver diseases and explore the possible prognostic factors.
  • CONCLUSION: Emergency liver transplantation is an effective treatment to salvage patients in end-stage.
  • [MeSH-major] Hepatitis B / surgery. Liver Cirrhosis / surgery. Liver Transplantation

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16686060.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] AYI8EX34EU / Creatinine
  •  go-up   go-down


11. Deaciuc IV, Song Z, Peng X, Barve SS, Song M, He Q, Knudsen TB, Singh AV, McClain CJ: Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease. Hepatol Int; 2008 Mar;2(1):39-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide transcriptome expression in the liver of a mouse model of high carbohydrate diet-induced liver steatosis and its significance for the disease.
  • PURPOSE: To perform a large-scale gene profiling of the liver in a mouse model of fatty liver induced by high carbohydrate (sucrose) diet (HCD) to gain a deeper insight into potential mechanisms of diet-induced hepatic steatosis.
  • HCD feeding led to marked liver steatosis without inflammation or necrosis.
  • The genes that underwent expression changes perform a large variety of molecular functions, and the vast majority of these have never been tested before in non-alcoholic fatty liver of nutritional origin.
  • They reveal novel aspects of the disease and allow identification of candidate genes that may underlie the initiation of hepatic steatosis and progression to non-alcoholic steatohepatitis.
  • CONCLUSIONS: HCD-fed laboratory animals provide a model of early non-alcoholic fatty liver disease resembling the disease in humans.
  • The genome wide gene profiling of the liver reveals the complexity of the disease, unravels novel aspects of HCD-induced hepatic steatosis, and helps elucidate its nature and mechanisms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nutr Biochem. 2007 Mar;18(3):184-95 [17296492.001]
  • [Cites] Am J Clin Nutr. 1980 May;33(5):1108-39 [6989228.001]
  • [Cites] Ann Intern Med. 2005 Nov 15;143(10):722-8 [16287793.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1663-74 [16285964.001]
  • [Cites] Hepatology. 2005 Oct;42(4):905-14 [16175602.001]
  • [Cites] J Biol Chem. 2005 May 20;280(20):20010-20 [15753094.001]
  • [Cites] J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):99-105 [15860251.001]
  • [Cites] CMAJ. 2005 Mar 29;172(7):899-905 [15795412.001]
  • [Cites] Clin Biochem. 2005 Mar;38(3):203-17 [15708540.001]
  • [Cites] Alcohol. 2004 Aug;34(1):67-79 [15670668.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] Biochimie. 2004 Nov;86(11):839-48 [15589694.001]
  • [Cites] Proc Natl Acad Sci U S A. 1964 Nov;52:1255-63 [14231450.001]
  • [Cites] J Biol Chem. 1962 Dec;237:3640-8 [13990010.001]
  • [Cites] Hepatology. 1999 May;29(5):1602-4 [10216149.001]
  • [Cites] Adv Enzyme Regul. 1996;36:199-226 [8869748.001]
  • [Cites] Ann N Y Acad Sci. 1982;393:32-47 [6959560.001]
  • [Cites] Clin Liver Dis. 2004 Aug;8(3):559-74, ix [15331064.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36650-9 [15194686.001]
  • [Cites] J Clin Invest. 2004 Jul;114(2):147-52 [15254578.001]
  • [Cites] Alcohol. 2004 Feb;32(2):113-27 [15163562.001]
  • [Cites] Am J Clin Nutr. 2004 Mar;79(3):502-9 [14985228.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):219-27 [14739091.001]
  • [Cites] J Hepatol. 2003 Dec;39(6):978-83 [14642615.001]
  • [Cites] J Lipid Res. 2003 Apr;44(4):846-53 [12562844.001]
  • [Cites] Am J Clin Nutr. 2003 Jan;77(1):43-50 [12499321.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;967:19-27 [12079831.001]
  • [Cites] Hepatology. 2001 May;33(5):1239-58 [11343254.001]
  • [Cites] J Soc Biol. 2001;195(3):243-8 [11833461.001]
  • [Cites] Semin Liver Dis. 2001;21(1):89-104 [11296700.001]
  • [Cites] Gene Expr. 2000;9(1-2):63-75 [11097425.001]
  • [Cites] Eur J Biochem. 2001 Jan;268(1):1-6 [11121095.001]
  • [Cites] J Clin Invest. 1996 May 1;97(9):2081-91 [8621798.001]
  • [Cites] Environ Res. 1992 Oct;59(1):238-49 [1425514.001]
  • [Cites] J Pediatr. 2005 Dec;147(6):835-8 [16356442.001]
  • (PMID = 19669278.001).
  • [ISSN] 1936-0533
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2716868
  •  go-up   go-down


12. Rakela B J: [Liver disease recurrence after liver transplantation]. Rev Med Chil; 2010 Apr;138(4):504-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver disease recurrence after liver transplantation].
  • [Transliterated title] Recurrencia de la enfermedad hepática primaria después del trasplante hepático.
  • Liver transplantation has become a standard option in the management of patients with end-stage liver disease.
  • It is now evident that the most common etiology of long-term graft dysfunction is the recurrence of the primary liver disease.
  • Autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis recur between 15 to 30% of the graft recipients.
  • The clinical expression of this recurrence tends to be milder; the diagnosis is only established in many patients by findings in the liver biopsy.
  • The recurrence of hepatitis C virus infection is characterized by an accelerated progression towards cirrhosis and hepatic failure due to the lack of an effective immunoprophylaxis program and an effective antiviral therapy.
  • The liver from these patients, apart from producing this abnormal protein, is otherwise normal, and has been used as an organ for recipients in dire need of a liver transplant, such as patients with hepatocellular carcinoma.
  • This approach is known as domino liver transplantation.
  • As these recipients are followed long term, they may develop de novo amyloidosis.
  • In summary, the underlying liver condition that led to endstage liver disease and liver transplantation may recur after liver transplantation.
  • The clinical expression of the recurrence of the hepatic disease is modulated by the immunosuppression program unless we have an effective immunoprophylaxis and antiviral agents such as in hepatitis B.
  • [MeSH-major] Cholangitis, Sclerosing. Hepatitis, Autoimmune. Liver Cirrhosis, Biliary / prevention & control. Liver Transplantation. Postoperative Complications


13. Malik R, Saich R, Rahman T, Hodgson H: During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease. Dig Dis Sci; 2006 Dec;51(12):2235-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] During thioacetamide-induced acute liver failure, the proliferative response of hepatocytes to thyroid hormone is maintained, indicating a potential therapeutic approach to toxin-induced liver disease.
  • In toxic liver injury, proliferation of preexisting hepatocytes helps restore liver mass and function.
  • While loss of liver mass per se stimulates hepatocyte proliferation, exogenous mitogens have a potential role in enhancing liver regeneration.
  • The aim of this study was to characterize the effects of the mitogen, tri-iodothyonine, on the regenerative capacity of hepatocytes during thioacetamide-induced liver failure.
  • Liver cell proliferation was assessed and comparison made with other control groups receiving tri-iodothyonine or vehicle only.
  • We conclude that the ability of hepatocytes in the midzonal areas of rat liver to proliferate in response to tri-iodothyonine is maintained during severe acute toxic injury.
  • [MeSH-major] Cell Proliferation / drug effects. Hepatocytes / drug effects. Liver Failure, Acute / pathology. Triiodothyronine / pharmacology
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Liver Regeneration / drug effects. Male. Mitogens / pharmacology. Random Allocation. Rats. Thioacetamide

  • Hazardous Substances Data Bank. THIOACETAMIDE .
  • Hazardous Substances Data Bank. LIOTHYRONINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 1990 May;10(3):332-6 [2195108.001]
  • [Cites] Am J Pathol. 1991 Sep;139(3):535-52 [1716045.001]
  • [Cites] Am J Surg. 2002 Apr;183(4):457-63 [11975936.001]
  • [Cites] Res Commun Mol Pathol Pharmacol. 1994 Aug;85(2):157-62 [7994560.001]
  • [Cites] Liver. 1999 Dec;19(6):519-25 [10661686.001]
  • [Cites] Semin Liver Dis. 2003 Aug;23(3):203-15 [14523674.001]
  • [Cites] Physiol Rev. 1986 Jul;66(3):499-541 [2426724.001]
  • [Cites] J Surg Res. 2001 Aug;99(2):385-96 [11469916.001]
  • [Cites] Hepatology. 1994 Nov;20(5):1237-41 [7927257.001]
  • [Cites] Am J Pathol. 1991 Nov;139(5):1099-109 [1683163.001]
  • [Cites] Oncogene. 1997 Feb 20;14(7):857-63 [9047393.001]
  • [Cites] Semin Cell Dev Biol. 2002 Dec;13(6):425-31 [12468243.001]
  • [Cites] Hepatology. 2003 Jan;37(1):79-86 [12500192.001]
  • [Cites] Dig Dis Sci. 2002 Oct;47(10):2170-8 [12395888.001]
  • [Cites] Science. 1997 Apr 4;276(5309):60-6 [9082986.001]
  • [Cites] Life Sci. 2003 Jan 3;72 (7):851-61 [12479984.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1013-20 [9537441.001]
  • [Cites] FASEB J. 1996 Aug;10(10):1118-28 [8751714.001]
  • [Cites] Am J Pathol. 1996 Mar;148(3):815-24 [8774136.001]
  • [Cites] J Hepatol. 2003 May;38(5):583-90 [12713868.001]
  • [Cites] Arch Surg. 2001 Dec;136(12):1377-80 [11735863.001]
  • [Cites] Lab Invest. 1983 Feb;48(2):224-30 [6823098.001]
  • [Cites] Endocrinology. 2002 Mar;143(3):979-84 [11861522.001]
  • [Cites] Int J Exp Pathol. 2000 Apr;81(2):145-57 [10762442.001]
  • (PMID = 17080250.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitogens; 06LU7C9H1V / Triiodothyronine; 075T165X8M / Thioacetamide
  •  go-up   go-down


1
Advertisement
4. Sańko-Resmer J, Paczek L, Wyzgał J, Ziółkowski J, Ciszek M, Alsharabi A, Grzelak I, Paluszkiewicz R, Patkowski W, Krawczyk M: Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation. Transplant Proc; 2006 Jan-Feb;38(1):212-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biliary liver cirrhosis secondary to cystic fibrosis: a rare indication for liver transplantation.
  • As more effective therapies prolong the lives of patients with cystic fibrosis, there are now more patients in this population diagnosed with liver diseases.
  • Liver transplantation is an accepted method of treatment for children with cystic fibrosis and portal hypertension.
  • We present our first case of orthotopic liver transplantation performed in a 29-year-old man with cystic fibrosis.
  • [MeSH-major] Cystic Fibrosis / diagnosis. Liver Cirrhosis, Biliary / etiology. Liver Cirrhosis, Biliary / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Male. Treatment Outcome


15. Natsume T, Okazumi S, Takayama W, Takeda A, Iwasaki K, Makino H, Sasagawa S, Cho A, Kouno T, Kondo S, Sunouchi K, Asano T, Ochiai T: Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT. Hepatogastroenterology; 2007 Sep;54(78):1745-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the hepatic blood flow increase in the cases with liver metastasis and prediction of patent cases of liver metastasis using dynamic CT.
  • BACKGROUND/AIMS: This study aimed to measure hepatic blood flow increase in cases with liver metastasis and to diagnose minimal metastasis which cannot be visualized by imaging modalities.
  • METHODOLOGY: The evaluation of hepatic arterial flow increase was performed quantitatively by newly devised index ELR (early-late-ratio) using dynamic computed tomographic (CT) scanning with contrast media.
  • RESULTS: The ratio of the cases with liver metastasis was significantly higher than that of normal liver control.
  • It was revealed that the ratio was correlated with microvessel proliferation in the liver around the metastasis by examination of surgical specimen.
  • CONCLUSIONS: ELR not only was useful to evaluate hepatic blood flow increase in the cases with liver metastasis but also could be applied to predict the patent group with micrometastasis.
  • [MeSH-major] Liver / blood supply. Liver Neoplasms / blood supply. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Regional Blood Flow. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Blood Flow Velocity. Case-Control Studies. Cell Proliferation. Densitometry. Hepatic Artery / pathology. Humans. Microcirculation. Neoplasm Metastasis. Time Factors

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18019709.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


16. Terán A, Casafont F, Fábrega E, Martínez-Taboada VM, Rodríguez-Valverde V, Pons-Romero F: [Adult-onset Still's disease with liver failure requiring liver transplantation]. Gastroenterol Hepatol; 2009 Dec;32(10):681-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset Still's disease with liver failure requiring liver transplantation].
  • [Transliterated title] Enfermedad de Still del adulto con desarrollo de insuficiencia hepática que precisa trasplante hepático.
  • We present the case of a 23-year-old man with fever of unknown origin, who developed acute liver failure 2 months after symptom onset, requiring an urgent liver transplantation.
  • The diagnosis of adult-onset Still's disease was established after the reappearance of symptoms after transplantation, and high doses of corticosteroids were used to control disease activity.
  • [MeSH-major] Liver Failure / etiology. Liver Transplantation. Still's Disease, Adult-Onset / surgery


17. Heilmaier C, Sutter R, Lutz AM, Seifert B, Willmann JK: [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session]. Rofo; 2008 May;180(5):440-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dynamic MRI of the liver with parallel acquisition technique: characterization of focal liver lesions and analysis of the hepatic vasculature in a single MRI session].
  • [Transliterated title] Dynamische MRT der leber mit paralleler akquisitionstechnik: charakterisierung fokaler leberläsionen und analyse des gefässstatus in einem untersuchungsgang.
  • PURPOSE: To retrospectively evaluate the performance of breath-hold contrast-enhanced 3D dynamic parallel gradient echo MRI (pMRT) for the characterization of focal liver lesions (standard of reference: histology) and for the analysis of hepatic vasculature (standard of reference: contrast-enhanced 64-detector row computed tomography;.
  • MATERIALS AND METHOD: Two blinded readers independently analyzed preoperative pMRT data sets (1.5T-MRT) of 45 patients (23 men, 22 women; 28 - 77 years, average age, 48 years) with a total of 68 focal liver lesions with regard to image quality of hepatic arteries, portal and hepatic veins, presence of variant anatomy of the hepatic vasculature, as well as presence of portal vein thrombosis and hemodynamically significant arterial stenosis.
  • In addition, both readers were asked to identify and characterize focal liver lesions.
  • RESULTS: Based on histology, the 68 liver lesions were found to be 42 hepatocellular carcinomas (HCC), 20 metastases, 3 cholangiocellular carcinomas (CCC) as well as 1 dysplastic nodule, 1 focal nodular hyperplasia (FNH) and 1 atypical hemangioma.
  • Overall, the diagnostic accuracy was high for both readers (91 - 100 %) in the characterization of these focal liver lesions with an excellent interobserver agreement (kappa-values of 0.89 [metastases], 0.97 [HCC] and 1 [CCC]).
  • Anatomical variants of the hepatic arteries, hepatic veins and portal vein as well as thrombosis of the portal vein were reliably detected by pMRT.
  • It allows reliable detection and characterization of focal liver lesions as well as the depiction of hepatic vascular variants, portal vein thrombosis, and arterial stenosis.
  • Introducing pMRT in routine liver MRI may be another step towards a simplified diagnostic work-up prior to liver surgery.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Cholangiocarcinoma / diagnosis. Image Enhancement / methods. Image Processing, Computer-Assisted / methods. Liver / blood supply. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Arterial Occlusive Diseases / diagnosis. Bile Duct Neoplasms / blood supply. Bile Duct Neoplasms / diagnosis. Bile Duct Neoplasms / surgery. Female. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Hepatic Artery / pathology. Hepatic Veins / pathology. Humans. Male. Middle Aged. Observer Variation. Portal Vein / pathology. Retrospective Studies. Sensitivity and Specificity. Thrombosis / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18438745.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Polacco M, Vitale A, Valmasoni M, D'Amico F, Gringeri E, Brolese A, Zanus G, Neri D, Carraro A, Pauletto A, Romanelli E, Lo Bello S, Cillo U: Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report. Transplant Proc; 2010 May;42(4):1378-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection associated with mini porto-caval shunt as salvage treatment in patients with progression of hepatocellular carcinoma before liver transplantation: a case report.
  • Tumor progression before orthotopic liver transplantation (OLT) is the main cause of dropouts from waiting lists among patients with hepatocellular carcinoma (HCC).
  • Performing a porto-caval shunt (PCS) before parenchymal liver transection has the potential to allow an extended hepatectomy in patients with decompensated liver cirrhosis, reducing portal hyperflow and therefore the sinusoidal shear-stress on the remnant liver.
  • We report the case of a 59-year-old man affected by hepatitis C virus (HCV)-related decompensated liver cirrhosis (Child Pugh score presentation, C-10; Model for End Stage Liver Disease score, 18) and HCC (2 lesions of 2 and 2.8 cm).
  • The patient began the evaluation to join the OLT waiting list, but, in the 3 months required to complete the evaluation, he developed tumor progression: 3 HCC lesions, the largest 1 with a diameter of about 4.4 cm.
  • After appropriate preoperative studies, the patient underwent a major liver resection (trisegmentectomy) after side-to-side PCS by interposition of an iliac vein graft from a cadaveric donor.
  • Associating a partial side-to-side PCS with hepatic resection may represent a potential salvage therapy for patients with decompensated cirrhosis and HCC progression beyond listing criteria for OLT.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Cirrhosis / surgery. Liver Neoplasms / surgery. Liver Transplantation / methods. Portasystemic Shunt, Transjugular Intrahepatic / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20534307.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunosuppressive Agents; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


19. Zurbuchen U, Holmer C, Lehmann KS, Stein T, Roggan A, Seifarth C, Buhr HJ, Ritz JP: Determination of the temperature-dependent electric conductivity of liver tissue ex vivo and in vivo: Importance for therapy planning for the radiofrequency ablation of liver tumours. Int J Hyperthermia; 2010 Feb;26(1):26-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of the temperature-dependent electric conductivity of liver tissue ex vivo and in vivo: Importance for therapy planning for the radiofrequency ablation of liver tumours.
  • INTRODUCTION: Knowledge about the changes in the electric conductivity during the coagulation process of radiofrequency ablation of the liver is a prerequisite for the predictability of produceable thermonecrosis in the liver.
  • MATERIALS AND METHODS: Continuous measurements of the electric conductivity sigma in ex vivo porcine liver (n = 25) were done during the coagulation and cooling process at the temperature range of the radiofrequency ablation at a frequency of 470 kHz relevant for the radiofrequency ablation.
  • Measurements of the electric conductivity were performed in both perfused porcine liver (n = 3) and a human surgical specimen from a colorectal liver metastasis.
  • At 37 degrees C, the specific conductance sigma in the healthy perfused porcine liver was 0.52 S/m, 0.55 S/m and 0.57 S/m (mean 0.55 S/m).
  • The electric conductivity of the human colorectal liver metastasis was clearly higher.
  • [MeSH-major] Catheter Ablation / methods. Electric Conductivity. Liver / physiopathology. Liver Neoplasms / physiopathology
  • [MeSH-minor] Animals. Colorectal Neoplasms / pathology. Humans. Swine. Temperature

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20100050.001).
  • [ISSN] 1464-5157
  • [Journal-full-title] International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  • [ISO-abbreviation] Int J Hyperthermia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Culafić DM, Lekić NS, Kerkez MD, Mijac DD: Liver actinomycosis mimicking liver tumour. Vojnosanit Pregl; 2009 Nov;66(11):924-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver actinomycosis mimicking liver tumour.
  • BACKGROUND: The liver actinomycosis is a rare disease associated with complex differentiation from the liver metastases or hepatocellular carcinoma.
  • Diagnostic procedures that followed, including abdominal ultrasound and computed tomography led us to the diagnosis of metastatic liver disease of unknown etiology with pleural and pericardial effusion.
  • Intraoperatively, the presence of liver pseudotumor without malignancy in the liver was confirmed.
  • Histological examination confirmed the diagnosis of liver actinomycosis.
  • CONCLUSION: Liver actinomycosis has a nonspecific presentation, often mimicking liver tumor.
  • A timely diagnosis as well as a combined surgical and antibiotic therapy is necessary in the treatment of patients with primary disease and prevention of complications.
  • [MeSH-major] Actinomycosis / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Diagnostic Errors. Female. Humans. Middle Aged


21. Yuan Y, Song B, Wu B, Xu J, Li YC: [Research on relationship between preoperative CT volumetry of donor' s liver and intraoperative weight measurement of liver for living related liver transplantation]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Jun;38(3):526-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research on relationship between preoperative CT volumetry of donor' s liver and intraoperative weight measurement of liver for living related liver transplantation].
  • OBJECTIVE: To investigate the relationship between the donor liver volume calculated by 16-slice multi-detector-row CT before living related liver transplantation (LRLT) and the hepatic weight measured during the operation, and try to get an equation to express the relation of associating volume with weight of transplanted liver.
  • The imaging data at the hepatic venous phase was used for whole and partial liver volumetry processed or measured on a dedicated image post-processing workstation.
  • The resected part of donor liver was weighed during the operation.
  • Statistical analysis was used to test the relationship between the CT-measured liver volume and the actual weight of resected liver part, and the relationship was expressed by scatter graph and linear equation.
  • RESULTS: The mean of liver volumes calculated by CT before operation was (699. 47 +/- 140.
  • 18) mL, the mean weight of donated livers measured during operation was (532. 14+/- 98.
  • CONCLUSION: The correlation equation between the donor liver volume calculated by CT preoperatively and the grafted liver weight measured during operation can be used to accurately estimate the desired liver mass for LRLT, which is very helpful for donor selection and preoperative planning.
  • [MeSH-major] Liver / anatomy & histology. Liver / radiography. Liver Transplantation. Living Donors. Preoperative Period. Tomography, X-Ray Computed


22. Reddy MS, Smith L, Jaques BC, Agarwal K, Hudson M, Talbot D, Manas DM: Do laparoscopy and intraoperative ultrasound have a role in the assessment of patients with end-stage liver disease and hepatocellular carcinoma for liver transplantation? Transplant Proc; 2007 Jun;39(5):1474-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Do laparoscopy and intraoperative ultrasound have a role in the assessment of patients with end-stage liver disease and hepatocellular carcinoma for liver transplantation?
  • BACKGROUND: Liver transplantation is the treatment of choice for patients with end-stage liver disease (ESLD) and early hepatocellular carcinoma (HCC), Routine laparoscopy with intraoperative ultrasound was employed in an attempt to improve patient selection for transplantation.
  • METHODS: We retrospectively reviewed the clinical notes and transplant database of all patients with ESLD complicated by HCC, being assessed for liver transplantation, from January 2000 to April 2005.
  • RESULTS: Twenty-five patients with ESLD and HCC underwent assessment for liver transplantation.
  • One patient was found to have lesser curvature lymphadenopathy, Two patients had major vascular involvement noted in the explanted liver.
  • CONCLUSIONS: As an additional investigation, laparoscopy did not improve staging or alter the management of patients with HCC being assessed for liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Failure / surgery. Liver Neoplasms / surgery. Ultrasonography
  • [MeSH-minor] Humans. Laparoscopy. Monitoring, Intraoperative. Neoplasm Staging. Retrospective Studies


23. Qian Y, Fan JG: Obesity, fatty liver and liver cancer. Hepatobiliary Pancreat Dis Int; 2005 May;4(2):173-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Obesity, fatty liver and liver cancer.
  • BACKGROUND: It has been suggested that obesity and fatty liver may be associated with the morbidity and mortality of liver cancer, and the early diagnosis and effective treatment of fatty liver coupled with liver cancer are supposed to improve the prognosis of obese patients.
  • This review was attempted to understand the relationship between obesity, fatty liver and liver cancer.
  • DATA RESOURCES: An English-language literature search using PUBMED (1990-2004) on obesity, fatty liver and liver cancer and other related articles in Chinese.
  • RESULTS: Obesity is associated with the risk of death from all cancers and from cancers at individual sites including liver cancer, and it is an independent risk factor for hepatocellular carcinoma (HCC) in patients with alcoholic cirrhosis and cryptogenic cirrhosis.
  • More frequent surveillance for HCC may be warranted in obese patients with fatty liver and attempts should be made to interrupt the progression from simple hepatic steatosis to steatohepatitis, cirrhosis and ultimately HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Fatty Liver / epidemiology. Liver Neoplasms / epidemiology. Obesity / epidemiology

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15908310.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 27
  •  go-up   go-down


24. Rodríguez G, Gallego S, Breidenassel C, Moreno LA, Gottrand F: Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents? Nutr Hosp; 2010 Sep-Oct;25(5):712-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents?
  • Pediatric obesity has increased dramatically all over the world and nonalcoholic fatty liver disease (NAFLD) is one of the most frequent complications associated with excess adiposity.
  • NAFLD causes serum transaminase elevation and liver disease, which could end up in fibrosis, cirrhosis and eventually hepatocellular carcinoma.
  • The aim of the present article is to review the role of serum liver enzyme assessment as a suitable non invasive predictor of NAFLD in children.
  • Although serum liver enzyme elevation does not accurately measure liver damage, it may be a valuable and non invasive test to screen NAFLD in children and adolescents and a marker to control NAFLD evolution.
  • [MeSH-major] Fatty Liver / diagnosis. Liver / enzymology. Liver Function Tests. Obesity / complications. Transaminases / analysis


25. Oliveri F, Coco B, Ciccorossi P, Colombatto P, Romagnoli V, Cherubini B, Bonino F, Brunetto MR: Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World J Gastroenterol; 2008 Oct 28;14(40):6154-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases.
  • AIM: To investigate the usefulness of transient elastography by Fibroscan (FS), a rapid non-invasive technique to evaluate liver fibrosis, in the management of chronic hepatitis B virus (HBV) carriers.
  • METHODS: In 297 consecutive HBV carriers, we studied the correlation between liver stiffness (LS), stage of liver disease and other factors potentially influencing FS measurements.
  • We identified the cut-offs of 7.5 and 11.8 kPa for the diagnosis of fibrosis >or= S3 and cirrhosis respectively, showing 93.9% and 86.5% sensitivity, 88.5% and 96.3% specificity, 76.7% and 86.7% positive predictive value (PPV), 97.3% and 96.3% negative predictive value (NPV) and 90.1% and 94.2% diagnostic accuracy.
  • CONCLUSION: FS is a non-invasive tool to monitor liver disease in chronic HBV carriers, provided that the pattern of biochemical activity is taken into account.
  • In the inactive carrier, it identifies non-HBV-related causes of liver damage and transient reactivations.
  • In CHB patients, it may warrant a more appropriate timing of control liver biopsies.
  • [MeSH-major] Alanine Transaminase / blood. Carrier State. Clinical Enzyme Tests. Elasticity Imaging Techniques. Hepatitis B / diagnosis. Hepatitis B, Chronic / diagnosis. Liver / pathology. Liver Cirrhosis / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003;39 Suppl 1:S3-25 [14708673.001]
  • [Cites] Ultrasound Med Biol. 2003 Dec;29(12):1705-13 [14698338.001]
  • [Cites] J Viral Hepat. 1996 Nov;3(6):277-83 [8947878.001]
  • [Cites] Gastroenterology. 2005 Feb;128(2):343-50 [15685546.001]
  • [Cites] Hepatology. 2005 Jan;41(1):48-54 [15690481.001]
  • [Cites] Hepatology. 2005 Oct;42(4):838-45 [16121354.001]
  • [Cites] J Acquir Immune Defic Syndr. 2006 Feb 1;41(2):175-9 [16394849.001]
  • [Cites] Gut. 2006 Mar;55(3):403-8 [16020491.001]
  • [Cites] Semin Liver Dis. 2006 May;26(2):130-41 [16673291.001]
  • [Cites] Hepatology. 2006 Dec;44(6):1511-7 [17133503.001]
  • [Cites] Hepatology. 2007 Feb;45(2):507-39 [17256718.001]
  • [Cites] J Viral Hepat. 2007 May;14(5):360-9 [17439526.001]
  • [Cites] Gut. 2007 Jul;56(7):968-73 [17255218.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1057-70 [17654702.001]
  • [Cites] Hepatology. 2008 Feb;47(2):380-4 [18095306.001]
  • [Cites] Hepatology. 2008 Feb;47(2):592-5 [18098325.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):606-13 [18222014.001]
  • [Cites] J Hepatol. 2008 May;48(5):835-47 [18334275.001]
  • [Cites] J Hepatol. 2002 Feb;36(2):263-70 [11830339.001]
  • [Cites] IEEE Trans Ultrason Ferroelectr Freq Control. 2002 Apr;49(4):436-46 [11989699.001]
  • [Cites] Gut. 2003 Mar;52(3):416-9 [12584226.001]
  • [Cites] Gut. 2003 Mar;52(3):420-4 [12584227.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Mar;18(3):246-52 [12603523.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2261-7 [14572577.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • (PMID = 18985805.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antiviral Agents; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC2761576
  •  go-up   go-down


26. Zhong G, Hu J, Chen Z, Luo Y, Zhang Y, Yin Y, Li W, Yi Z, Chen G: [Effect of the formulae for calming the liver and suppressing YANG on lymphocyte proteome in migraine rats with syndrome of hyperactivity of liver-YANG]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Jan;35(1):70-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of the formulae for calming the liver and suppressing YANG on lymphocyte proteome in migraine rats with syndrome of hyperactivity of liver-YANG].
  • OBJECTIVE: To explore the molecular mechanism of the formulae for calming the liver and suppressing YANG in migraine rat model with syndrome of hyperactivity of the liver-YANG.
  • METHODS: A rat model of migraine with hyperactivity of liver-YANG was established through electrical trigeminal ganglion stimulation and syndrome of oral administration of Fuzi decoction.
  • The total proteins of the lymphocyte in the rats were separated by immobilized pH gradient-based 2-dimensional gel electrophoresis (2-DE), and the 2-DE image was analyzed by PDQuest 7.0 software.
  • RESULTS: The formulae for calming the liver and suppressing YANG could also improve headache.
  • Well-resolution and reproducible 2-DE patterns of rat lymphocyte from normal, model, and therapy tissues were obtained.
  • CONCLUSION: Differences occur in the expression of lymphocyte proteins in migraine rats with syndrome of hyperactivity of liver-YANG after treatment with the formulae for calming the liver and suppressing YANG, and the 11 identified protein spots may be associated with its mechanism.
  • [MeSH-minor] Animals. Diagnosis, Differential. Drugs, Chinese Herbal / therapeutic use. Electric Stimulation. Liver / physiopathology. Male. Proteins / analysis. Proteins / metabolism. Rats. Rats, Sprague-Dawley. Yin-Yang

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Migraine.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130367.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Proteins; 0 / Proteome
  •  go-up   go-down


27. Sahani DV, Kalva SP, Fischman AJ, Kadavigere R, Blake M, Hahn PF, Saini S: Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET. AJR Am J Roentgenol; 2005 Jul;185(1):239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of liver metastases from adenocarcinoma of the colon and pancreas: comparison of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET.
  • OBJECTIVE: The objective of our study was to assess the relative performance of mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET for the detection of liver metastases from adenocarcinoma of the colon and pancreas.
  • MATERIALS AND METHODS: Imaging data of 34 patients (23 men, 11 women; age range, 44-78 years) with adenocarcinoma of the colon (n = 27) or adenocarcinoma of the pancreas (n = 7) who had undergone mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were retrospectively reviewed for the presence and number of liver metastases.
  • RESULTS: Thirty patients had hepatic metastases and four had no hepatic metastases according to the standard of reference.
  • MRI detected more hepatic metastases than FDG PET (p = 0.016).
  • CONCLUSION: In patients with colon and pancreatic adenocarcinoma, high-spatial-resolution mangafodipir trisodium-enhanced liver MRI and whole-body FDG PET were comparable in the detection of patients with liver metastases.
  • However, significantly more and smaller liver metastases were detected on MRI than on FDG PET.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / pathology. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Disodium EDTA .
  • Hazardous Substances Data Bank. ETHYLENEDIAMINE TETRAACETIC ACID .
  • Hazardous Substances Data Bank. DISODIUM CALCIUM EDTA .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972430.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 42Z2K6ZL8P / Manganese; 5V5IOJ8338 / Pyridoxal Phosphate; 9G34HU7RV0 / Edetic Acid; P28BIW0UTB / N,N'-bis(pyridoxal-5-phosphate)ethylenediamine-N,N'-diacetic acid
  •  go-up   go-down


28. Burton JR Jr, Rosen HR: Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States. Clin Gastroenterol Hepatol; 2005 Jul;3(7):700-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver retransplantation for hepatitis C virus recurrence: a survey of liver transplant programs in the United States.
  • BACKGROUND & AIMS: Hepatitis C virus (HCV)-related liver failure is the leading indication for liver transplantation (LT).
  • To gain insight into how transplant centers are dealing with this issue and whether published prognostic factors are being used, we conducted a survey of liver transplant centers across the US in late 2003.
  • However, less than half thought international normalized ratio (INR), Model for End-Stage Liver Disease (MELD), and bilirubin were important factors.
  • [MeSH-major] Hepatitis C / surgery. Liver Transplantation / statistics & numerical data

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16206504.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Yin Z, Wang X, Li N, Ni X, Jiang F, Li Y, Li J: Immunological advantage on small bowel graft induced by simultaneously transplanted liver in porcine auxiliary liver/small bowel transplantation. Transplant Proc; 2006 Dec;38(10):3251-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological advantage on small bowel graft induced by simultaneously transplanted liver in porcine auxiliary liver/small bowel transplantation.
  • BACKGROUND: We developed a new porcine model for auxiliary liver/small bowel transplantation (LSBT).
  • The possible immunological advantage on small bowel graft induced by simultaneously transplanted liver in the large animal was assessed.
  • CONCLUSIONS: An immunological advantage on intestinal graft can be induced by simultaneously transplanted liver in auxiliary LSBT.
  • The liver graft may reduce the risk of intestinal rejection and thus protect the bowel graft.
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Intestine, Small / transplantation. Liver Transplantation / physiology. Transplantation, Homologous / physiology

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175239.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


30. Târcoveanu E, Vlad N, Moldovanu R, Georgescu St, Bradea C, Lupaşu C, Crumpei F, Vasilescu A, Strat V: [Pyogenic liver abscesses]. Chirurgia (Bucur); 2008 Jul-Aug;103(4):417-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pyogenic liver abscesses].
  • BACKGROUND: Pyogenic liver abscesses were a relative rare disease.
  • In the last decades the management of the liver abscesses was changed due to the new imaging and surgical techniques.
  • AIM: To evaluate the clinical features, imaging techniques and treatment of the liver abscesses.
  • RESULTS: Of the 71 patients with liver abscesses, 39 (54.9%) were included in group I and 32 (45.1%) in group II.
  • The male/female ratio was 49/22; liver abscesses were more frequent to the males, in group I (63.3%) and more frequent to the women, in group II (63.6%) (p = 0.035).
  • We noted, as associated disease: diabetes--16% (N = 12), liver cirrhosis--7% (N = 5), malignancies--4.2% (N = 3).
  • The etiology was diverse: 25.4% after hepatic hydatid cysts, 12.7% with biliary origin, 22.5% with hematogenous and phlebitis origin and 39.4% with unknown origin (cryptogenetic).
  • Treatment of the liver abscesses was surgical, by open (87.3%) or laparoscopic approach (8.5%), and percutaneous (ultrasound guided punction)--2.8%.
  • The intraoperative mean dimension of the liver abscesses was 74.26 +/- 4.35 mm (range 30-160), similar with dimensions measured by echography 72.29 +/- 4.84 mm (range 12-179)--p < 10(-3).
  • Univariate analysis revealed as prognosis factors for intraoperative bleeding, diameter of the liver abscess (p < 10(-3)), dimension of the residual cavity (p < 10(-3)) and the pus volume (p < 10(-3)).
  • CONCLUSIONS: Pyogenic liver abscess is a challenging disease with high rate of postoperative morbidity.
  • Most of the abscesses are unique and situated in the right lobe of the liver.
  • The imaging techniques, especially ultrasound exam and CT-scan, are essential for the diagnosis and the treatment of liver abscesses.
  • [MeSH-major] Hepatectomy. Liver Abscess, Pyogenic / microbiology. Liver Abscess, Pyogenic / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780615.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Historical Article; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


31. Marangoni G, Faraj W, Sethi H, Rela M, Muiesan P, Heaton N: Liver resection in liver transplant recipients. Hepatobiliary Pancreat Dis Int; 2008 Dec;7(6):590-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection in liver transplant recipients.
  • BACKGROUND: Liver resection after liver transplantation is a relatively uncommon procedure.
  • Indications for liver resection include hepatic artery thrombosis (HAT), non-anastomotic biliary stricture (ischemic biliary lesions), liver abscess, liver trauma and recurrence of hepatocellular carcinoma (HCC).
  • METHODS: Eleven resections at a mean of 59 months after liver transplantation were made over 18 years.
  • Indications for liver resection included HCC recurrence in 4 patients, ischemic cholangiopathy, segmental HAT, sepsis and infected hematoma in 2 each, and ischemic segment IV after split liver transplantation in 1.
  • There were 3 deaths, two from HCC recurrence and one from post-transplant lymphoproliferative disorder.
  • CONCLUSIONS: Liver resection in liver transplant recipients is safe, and has good outcome in selected patients and avoids re-transplantation in the majority of patients.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Transplantation / statistics & numerical data. Postoperative Complications / mortality. Postoperative Complications / surgery
  • [MeSH-minor] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Child. Child, Preschool. Cholestasis / mortality. Cholestasis / surgery. Follow-Up Studies. Hospital Mortality. Humans. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Reoperation / mortality. Reoperation / statistics & numerical data. Thrombosis / mortality. Thrombosis / surgery


32. Vennarecci G, Ettorre GM, Lorusso R, Santoro R, Visco G, Santoro E: [Surgical prospects for liver metastases]. Chir Ital; 2007 Jan-Feb;59(1):27-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical prospects for liver metastases].
  • The recent advances in liver surgery have made it possible to perform liver resections in an increasing number of patients with consequent improvement in the results.
  • This coincides with an amplification of the indications to liver surgery for metastases.
  • Besides the development of radiological procedures as applied to liver surgery and more effective chemotherapy protocols, the actual approach to patients with liver metastases is shared by three figures - the surgeon, the radiologist and the oncologist.
  • Currently it has been shown that liver resections for metastases are possible with a meaningful increase of survival in the case of colorectal and neuroendocrine liver metastases and in selected cases of non-colorectal non-neuroendocrine metastases.
  • From the technical point of view the most remarkable aspect is the possibility of expanding the criteria of resectability by means of liver resections in one or two steps associated with portal vein embolisation or ligation of a portal branch.
  • It is also possible to perform iterative liver resections and liver transplantation in selected cases of neuroendocrine liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Neuroendocrine Tumors / secondary. Neuroendocrine Tumors / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17361929.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 67
  •  go-up   go-down


33. Tanikawa K, Torimura T: Studies on oxidative stress in liver diseases: important future trends in liver research. Med Mol Morphol; 2006 Mar;39(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies on oxidative stress in liver diseases: important future trends in liver research.
  • Oxidative stress has recently been shown to play an important role in various liver diseases.
  • Therefore, further studies on oxidative stress in liver diseases are urgently required.
  • [MeSH-major] Biomedical Research / trends. Liver / pathology. Liver Diseases / metabolism. Liver Diseases / pathology. Oxidative Stress

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1993 Jan 1;259(5091):87-91 [7678183.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1117-23 [10833486.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1796-807 [14724832.001]
  • [Cites] Kurume Med J. 1964;11:177-81 [14301621.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):568-71 [11832470.001]
  • [Cites] Circulation. 2003 Jul 29;108(4):414-9 [12860911.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):307-12 [11201732.001]
  • [Cites] J Clin Pathol. 1997 May;50(5):401-6 [9215123.001]
  • [Cites] J Hepatol. 2005 Oct;43(4):599-605 [16024129.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2198-205 [10445550.001]
  • [Cites] Hepatol Res. 2005 Oct;33(2):97-9 [16216545.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):430-4 [10488700.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1399-410 [11984526.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):291-300 [12105857.001]
  • [Cites] J Hepatol. 2000 Oct;33(4):616-22 [11059866.001]
  • [Cites] J Clin Invest. 2000 Jul;106(2):171-6 [10903330.001]
  • [Cites] Gastroenterol Jpn. 1989 Dec;24(6):655-62 [2514117.001]
  • (PMID = 16575511.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 23
  •  go-up   go-down


34. Yilmaz Y, Alahdab YO, Yonal O, Kurt R, Kedrah AE, Celikel CA, Ozdogan O, Duman D, Imeryuz N, Avsar E, Kalayci C: Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism; 2010 Sep;59(9):1327-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis.
  • Recent evidence has suggested an association between microalbuminuria and ultrasound-diagnosed nonalcoholic fatty liver disease (NAFLD) in patients with diabetes and prediabetes.
  • We thus evaluated the relationships between microalbuminuria and liver histology in a hospital-based sample of 87 adults with biopsy-proven NAFLD from Turkey.
  • There were no differences in the prevalence of microalbuminuria in patients with definite nonalcoholic steatohepatitis, borderline nonalcoholic steatohepatitis, and simple fatty liver.
  • [MeSH-major] Albuminuria / complications. Fatty Liver / complications. Liver / pathology. Liver Cirrhosis / complications

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Metabolism. 2010 Sep;59(9):E5; author reply E6 [20417942.001]
  • (PMID = 20096896.001).
  • [ISSN] 1532-8600
  • [Journal-full-title] Metabolism: clinical and experimental
  • [ISO-abbreviation] Metab. Clin. Exp.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Tangkijvanich P, Chanmee T, Komtong S, Mahachai V, Wisedopas N, Pothacharoen P, Kongtawelert P: Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol; 2010 Jan;25(1):129-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers.
  • BACKGROUND AND AIMS: The role of glypican-3 (GPC3), a novel serum marker, in differentiating hepatocellular carcinoma (HCC) from non-malignant chronic liver disease and other malignant space-occupying lesions in the liver is largely unknown.
  • METHODS: Six groups were studied which included 40 healthy subjects, 50 patients with chronic hepatitis (CH), 50 patients with liver cirrhosis (LC), 100 patients with HCC, 50 patients with intrahepatic cholangiocarcinoma (ICC) and 50 patients with metastatic carcinoma (MCA).
  • Detectable GPC3 was significantly correlated with the presence of viral hepatitis markers but was not correlated with tumor size and stage of HCC.
  • The combined use of serum GPC3 and AFP provides a potentially promising tool to better differentiate HCC from benign liver disorders, as well as from other liver cancers.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Hepatocellular / blood. Glypicans / blood. Liver Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / blood. Bile Duct Neoplasms / diagnosis. Bile Ducts, Intrahepatic / pathology. Cholangiocarcinoma / blood. Cholangiocarcinoma / diagnosis. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Hepatitis, Chronic / blood. Hepatitis, Chronic / diagnosis. Humans. Liver Cirrhosis / blood. Liver Cirrhosis / diagnosis. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. ROC Curve. Sensitivity and Specificity. Up-Regulation. alpha-Fetoproteins / analysis

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793164.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / Biomarkers, Tumor; 0 / GPC3 protein, human; 0 / Glypicans; 0 / alpha-Fetoproteins
  •  go-up   go-down


36. Gourtsoyianni S, Papanikolaou N, Yarmenitis S, Maris T, Karantanas A, Gourtsoyiannis N: Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions. Eur Radiol; 2008 Mar;18(3):486-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Respiratory gated diffusion-weighted imaging of the liver: value of apparent diffusion coefficient measurements in the differentiation between most commonly encountered benign and malignant focal liver lesions.
  • The purpose of this study was to measure apparent diffusion coefficient values of normal liver parenchyma and focal liver lesions utilizing a respiratory gated diffusion sequence with multiple b-values and to investigate whether apparent diffusion coefficient (ADC) measurements may be utilized to characterize and differentiate between malignant and benign focal hepatic lesions.
  • Thirty-eight consecutive patients underwent MRI of the liver including diffusion-weighted imaging (DWI).
  • ADC values were recorded on corresponding maps utilizing region of interest measurements in patients with benign (group A), malignant (group B) focal lesions and liver parenchyma (group C).
  • No focal lesions were detected in 11 patients, with a mean ADC value (CI 95%) of liver parenchyma 1.25x10(-3) mm2/s (1.21x10(-3) mm2/s-1.29x10(-3) mm2/s).
  • Differences in mean ADC of liver parenchyma between group A and B were not significant (p=0.054, 1.30x10(-3) mm2/s and 1.31x10(-3) mm2/s, respectively).
  • Mean ADC value (95% CI) of 22 benign lesions found in 18 patients was 2.55x10(-3) mm2/s (2.35x10(-3) mm2/s-2.74x10(-3) mm2/s), while the mean ADC value (95% CI) of 16 malignant lesions recorded in 9 patients was 1.04x10(-3) mm2/s (0.9x10(-3) mm2/s-1.17x10(-3) mm2/s).
  • The difference between mean ADC values of benign and malignant focal lesions was statistically significant (p<0.0001).
  • Respiratory gated diffusion-weighted imaging in the liver is technically feasible.
  • Apparent diffusion coefficient measurements can be useful in differentiating malignant from benign focal liver lesions.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Respiration

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuroimaging. 2003 Oct;13(4):330-8 [14569825.001]
  • [Cites] J Ultrasound Med. 2004 Feb;23 (2):207-15 [14992357.001]
  • [Cites] Eur Radiol. 2007 Jan;17(1):201-4 [16865369.001]
  • [Cites] AJR Am J Roentgenol. 2000 Oct;175(4):1111-20 [11000175.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1521-30 [17114546.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):831-7 [15720810.001]
  • [Cites] Radiology. 1999 Mar;210(3):617-23 [10207458.001]
  • [Cites] Clin Radiol. 2001 Feb;56(2):138-45 [11222073.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4175-9 [15736469.001]
  • [Cites] Jpn J Clin Oncol. 2004 Oct;34(10):620-6 [15591461.001]
  • [Cites] J Magn Reson Imaging. 2007 Jan;25(1):146-52 [17139633.001]
  • [Cites] NMR Biomed. 1995 Nov-Dec;8(7-8):289-96 [8739267.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1385-93 [17206421.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] Radiology. 2006 Jun;239(3):632-49 [16714455.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):397-402 [9456953.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 May;11(3):423-9 [2161612.001]
  • [Cites] Radiology. 1997 Sep;204(3):739-44 [9280252.001]
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):397-401 [11241813.001]
  • (PMID = 17994317.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Jin HB, Gu ZY, Yu CH, Li YM: Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients. Hepatobiliary Pancreat Dis Int; 2005 Aug;4(3):389-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of nonalcoholic fatty liver disease with type 2 diabetes: clinical features and independent risk factors in diabetic fatty liver patients.
  • BACKGROUND: Nonalcoholic fatty liver disease (NAFLDéis a common chronic liver disease in China, of which diabetic fatty liver (DFLéaccounts for a large proportion in clinic.
  • DFL is a disease without specific clinical features and lacking of confirmatory laboratory tests, and the etiology of hepatic steatosis remains poorly understood.
  • The aim of this paper was to explore the clinical characteristics and to determine associated risk factors in type 2 diabetes patients with fatty liver.
  • CONCLUSIONS: Dyslipidemia, dysglycemia and elevation of liver enzyme can be seen more frequently in the DFL patients than in the NDFL patients.
  • [MeSH-major] Diabetes Mellitus, Type 2 / complications. Fatty Liver / blood. Fatty Liver / etiology
  • [MeSH-minor] Aged. Alanine Transaminase / blood. Blood Glucose / metabolism. Case-Control Studies. Cholesterol, HDL / blood. Enzymes / blood. Female. Humans. Lipids / blood. Liver / enzymology. Male. Middle Aged. Risk Factors. Triglycerides / blood


38. De Leeuw K, Woestenburg A, Verbeelen D: Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis. NDT Plus; 2008 Dec;1(6):412-413
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lanthanum carbonate possibly responsible for acute liver failure in a patient with Child-Pugh stage A liver cirrhosis.
  • But there has been ongoing concern about lanthanum accumulation in tissues, especially in liver.
  • We describe the case of a woman with pre-existing liver disease, who presented with acute liver failure after introduction of lanthanum carbonate to her treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S79-86 [15508107.001]
  • [Cites] Kidney Int. 2005 Dec;68(6):2809-13 [16316357.001]
  • [Cites] Kidney Int. 2005 Mar;67(3):1062-9 [15698446.001]
  • [Cites] Semin Dial. 2006 May-Jun;19(3):195-9 [16689967.001]
  • [Cites] CNS Drugs. 2005;19(3):185-92 [15740174.001]
  • (PMID = 28657006.001).
  • [ISSN] 1753-0784
  • [Journal-full-title] NDT plus
  • [ISO-abbreviation] NDT Plus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; chronic renal failure / lanthanum carbonate / liver disease / phosphor
  •  go-up   go-down


39. Wiegard C, Lohse AW: [Liver and rheumatism]. Z Rheumatol; 2005 Feb;64(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver and rheumatism].
  • [Transliterated title] Leber und Rheuma.
  • There are multiple relations between rheumatic diseases and the liver, nevertheless the liver is extremely rare involved in rheumatic diseases.
  • "Elevated liver enzymes" are quite often found in patients who are under the medication with immunosuppressive drugs or/and non-steroidal antirheumatics.
  • The most frequent cause for "elevated liver enzymes" are toxic and allergic side effects of drugs; however, in rare cases it might be extremely helpful to examine, whether an independent liver disease exists.
  • Underlying liver diseases which might be associated with the rheumatic disorder or exist accidentally may change the therapeutic management of the patient.
  • If the liver disease present can cause the rheumatic disorder (e. g. virus-induced vasculitis, hemochromatosis), a specific hepatological therapy should precede the immunosuppression.
  • [MeSH-major] Antirheumatic Agents / adverse effects. Antirheumatic Agents / therapeutic use. Liver Diseases / complications. Liver Diseases / diagnosis. Rheumatic Diseases / complications. Rheumatic Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Metab Brain Dis. 2004 Dec;19(3-4):357-81 [15554428.001]
  • [Cites] Semin Oncol. 1992 Oct;19(5):551-65 [1411653.001]
  • [Cites] Semin Arthritis Rheum. 1992 Jun;21(6):376-86 [1626283.001]
  • [Cites] Q J Med. 1968 Jan;37(145):171-82 [5657764.001]
  • [Cites] Hepatology. 1990 May;11(5):730-4 [2347546.001]
  • [Cites] Nature. 1969 Aug 2;223(5205):472-6 [4894426.001]
  • [Cites] Intern Med. 2004 Mar;43(3):258-62 [15098613.001]
  • [Cites] J Hepatol. 1998 Mar;28(3):525-6 [9551696.001]
  • [Cites] Clin Rheumatol. 2003 Sep;22(3):234-6 [14505218.001]
  • [Cites] QJM. 2003 Nov;96(11):787-91 [14566034.001]
  • [Cites] J Viral Hepat. 2003 Jul;10 (4):298-305 [12823597.001]
  • [Cites] J Rheumatol. 2001 Nov;28(11):2466-73 [11708420.001]
  • [Cites] Medicine (Baltimore). 1980 Sep;59(5):367-79 [7432153.001]
  • [Cites] Curr Opin Rheumatol. 2004 Jan;16(1):62-6 [14673391.001]
  • [Cites] J Hepatol. 2001 Apr;34(4):631-5 [11394667.001]
  • [Cites] Lupus. 1993 Aug;2(4):275-9 [8268978.001]
  • [Cites] Arthritis Rheum. 2002 Dec;46(12):3317-26 [12483738.001]
  • [Cites] N Engl J Med. 2002 Sep 26;347(13):975-82 [12324553.001]
  • [Cites] Rheumatology (Oxford). 2002 Feb;41(2):176-9 [11886966.001]
  • [Cites] Best Pract Res Clin Rheumatol. 2004 Oct;18(5):663-76 [15454125.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2004 Aug;16(8):801-7 [15256984.001]
  • [Cites] Pediatr Dermatol. 2004 Sep-Oct;21(5):577-9 [15461767.001]
  • [Cites] Am J Pathol. 1978 Mar;90(3):619-32 [24342.001]
  • [Cites] Z Gastroenterol. 2003 Jun;41(6):517-22 [12806536.001]
  • (PMID = 15756497.001).
  • [ISSN] 0340-1855
  • [Journal-full-title] Zeitschrift fur Rheumatologie
  • [ISO-abbreviation] Z Rheumatol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 28
  •  go-up   go-down


40. Chan SC, Lo CM, Ng KK, Fan ST: Alleviating the burden of small-for-size graft in right liver living donor liver transplantation through accumulation of experience. Am J Transplant; 2010 Apr;10(4):859-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alleviating the burden of small-for-size graft in right liver living donor liver transplantation through accumulation of experience.
  • The issue of small-for-size graft (SFSG) containing the middle hepatic vein in right liver living donor liver transplantation from 1996 to 2008 (n = 320) was studied.
  • Characteristics of donors, grafts and recipients were comparable between Era I (first 50 cases) and Era II (next 270 cases) except that the median model for end-stage liver disease (MELD) score was higher in Era I (29 vs. 24; p = 0.024).
  • The median graft to standard liver volume ratio (G/SLV) in Era I was 49.0% (range, 32.8-86.2%), versus 49.3% (range, 28.4-89.4%) in Era II (p = 0.498).
  • [MeSH-major] Liver Transplantation. Living Donors

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148811.001).
  • [ISSN] 1600-6143
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Abboud G, Kaplowitz N: Drug-induced liver injury. Drug Saf; 2007;30(4):277-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Drug-induced liver injury.
  • Drug-induced liver injury is a frequent cause of hepatic dysfunction.
  • Reliably establishing whether the liver disease was caused by a drug requires the exclusion of other plausible causes and the search for a clinical drug signature.
  • The drug signature consists of the pattern of liver test abnormality, the duration of latency to symptomatic presentation, the presence or absence of immune-mediated hypersensitivity and the response to drug withdrawal.
  • Determination of causality also includes an evaluation of individual susceptibility to drug-induced liver injury.
  • Components of the drug signature in conjunction with certain risk factors have been incorporated into formal scoring systems that are predictive of the likelihood of drug-induced liver injury.
  • Mitigating the potential for drug-induced liver injury is achieved by the identification of toxicity signals during clinical trials and the monitoring of liver tests in clinical practice.
  • There are three signals of liver toxicity in clinical trials: (i) a statistically significant doubling (or more) in the incidence of serum alanine aminotransferase (ALT) elevation >3 x the upper limit of normal (ULN);.
  • Monitoring of liver tests in clinical practice has shown unconvincing efficacy, but where a benefit-risk analysis would favour continued therapy, monthly monitoring may have some benefit compared with no monitoring at all.
  • With rare exception, treatment of drug-induced liver injury is principally supportive.
  • Drug toxicity is the most common cause of acute liver failure, defined as a prolonged prothrombin time (international normalised ratio > or =1.5) and any degree of mental alteration occurring <26 weeks after the onset of illness in a patient without pre-existing cirrhosis.
  • A patient who meets these criteria must be evaluated for liver transplantation.
  • The pathogenesis of drug-induced liver injury can be examined on the basis of the two principal patterns of injury.
  • [MeSH-major] Chemical and Drug Induced Liver Injury. Drug-Related Side Effects and Adverse Reactions. Liver Diseases / diagnosis
  • [MeSH-minor] Animals. Drug Monitoring / methods. Humans. Liver / drug effects. Liver / pathology. Liver / physiopathology. Liver Function Tests. Models, Biological. Pharmaceutical Preparations / administration & dosage. Risk Factors

  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Res Toxicol. 2001 Feb;14 (2):175-81 [11258966.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1425-34 [12774022.001]
  • [Cites] Gastroenterology. 1997 Mar;112(3):923-34 [9041255.001]
  • [Cites] JAMA. 1999 Mar 17;281(11):1014-8 [10086436.001]
  • [Cites] Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S44-8 [14986274.001]
  • [Cites] Chem Res Toxicol. 2001 Jun;14(6):694-701 [11409940.001]
  • [Cites] Am J Med. 2003 Mar;114(4):299-306 [12681458.001]
  • [Cites] Hepatology. 2004 May;39(5):1430-40 [15122773.001]
  • [Cites] N Engl J Med. 1998 Mar 26;338(13):916-7 [9518284.001]
  • [Cites] Anesth Analg. 2002 Feb;94(2):243-9, table of contents [11812677.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Sep 24;226(3):695-702 [8831677.001]
  • [Cites] J Immunol. 1995 May 1;154(9):4333-40 [7722291.001]
  • [Cites] JAMA. 2002 May 1;287(17):2273-5 [11980528.001]
  • [Cites] Gut. 1989 Apr;30(4):515-9 [2714684.001]
  • [Cites] Clin Exp Allergy. 1998 Sep;28 Suppl 4:71-7 [9761038.001]
  • [Cites] Hepatology. 1999 Jan;29(1):1-4 [9862841.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1760-74 [15578514.001]
  • [Cites] J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S83-9 [15758665.001]
  • [Cites] J Infect Dis. 2005 Oct 15;192(8):1381-6 [16170755.001]
  • [Cites] JAMA. 1994 Dec 21;272(23 ):1845-50 [7990219.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27432-40 [11369777.001]
  • [Cites] Clin Liver Dis. 2006 May;10 (2):207-17, vii [16971258.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):802-11 [9466975.001]
  • [Cites] Hepatology. 2006 Jun;43(6):1220-30 [16729305.001]
  • [Cites] J Clin Epidemiol. 1993 Nov;46(11):1331-6 [8229111.001]
  • [Cites] Hepatology. 2005 Dec;42(6):1364-72 [16317692.001]
  • [Cites] Chest. 2005 Jul;128(1):116-23 [16002924.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1170-9 [15486922.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Surg Res. 1998 Dec;80(2):252-8 [9878321.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 Apr;15(4):231-3 [16552791.001]
  • [Cites] Pediatrics. 2006 Sep;118(3):e676-81 [16950959.001]
  • [Cites] Drug Metab Rev. 2004 May;36(2):301-12 [15237856.001]
  • [Cites] Chem Res Toxicol. 1998 Sep;11(9):969-88 [9760271.001]
  • [Cites] Science. 2001 Apr 27;292(5517):727-30 [11326099.001]
  • [Cites] Chem Res Toxicol. 2006 Feb;19(2):223-33 [16485898.001]
  • [Cites] Clin Pharmacol Ther. 2000 Apr;67(4):432-7 [10801254.001]
  • [Cites] J Hepatol. 1997;26 Suppl 1:23-30 [9138125.001]
  • [Cites] Dig Dis Sci. 1991 Sep;36(9):1223-8 [1716546.001]
  • [Cites] J Leukoc Biol. 1994 Mar;55(3):398-400 [7907127.001]
  • [Cites] Expert Opin Drug Metab Toxicol. 2006 Aug;2(4):493-503 [16859400.001]
  • [Cites] FASEB J. 2002 Aug;16(10 ):1227-36 [12153990.001]
  • [Cites] Gut. 1997 Oct;41(4):534-40 [9391255.001]
  • [Cites] Gastroenterology. 1990 Feb;98 (2):502-4 [2295408.001]
  • [Cites] Science. 2000 Feb 4;287(5454):860-4 [10657301.001]
  • [Cites] Gastroenterology. 2006 Mar;130(3):687-94 [16530510.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1603-12 [15185301.001]
  • [Cites] J Hepatol. 1997;26 Suppl 2:12-21 [9204405.001]
  • [Cites] Hepatology. 1992 Feb;15(2):244-51 [1735527.001]
  • [Cites] Science. 2001 Sep 7;293(5536):1829-32 [11546872.001]
  • [Cites] Mol Cell. 2002 Feb;9(2):423-32 [11864614.001]
  • [Cites] Toxicol Pathol. 1996 Mar-Apr;24(2):181-9 [8992608.001]
  • [Cites] Am J Pathol. 2000 Apr;156(4):1245-52 [10751350.001]
  • [Cites] Lancet. 2000 Nov 4;356(9241):1587-91 [11075787.001]
  • [Cites] Immunol Rev. 2000 Apr;174:5-20 [10807503.001]
  • [Cites] Gastroenterology. 2000 Feb;118(2):422-30 [10648470.001]
  • [Cites] J Immunol. 2000 Jun 15;164(12):6480-6 [10843705.001]
  • [Cites] Crit Rev Toxicol. 2005 Apr-May;35(4):325-61 [15989140.001]
  • [Cites] Hepatology. 2002 Aug;36(2):451-5 [12143055.001]
  • [Cites] Eur J Immunol. 2006 Apr;36(4):1028-38 [16552707.001]
  • [Cites] Drug Saf. 2001;24(7):483-90 [11444721.001]
  • [Cites] Annu Rev Immunol. 1994;12:991-1045 [8011301.001]
  • [Cites] Chem Res Toxicol. 1999 May;12(5):387-95 [10328748.001]
  • [Cites] Toxicol Sci. 2000 Apr;54(2):509-16 [10774834.001]
  • [Cites] Immunity. 2004 Oct;21(4):539-50 [15485631.001]
  • [Cites] Toxicology. 2001 Oct 5;167(1):73-81 [11557131.001]
  • [Cites] J Hepatol. 1997;26 Suppl 1:31-5 [9138126.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Apr 1;172(1):44-51 [11264022.001]
  • [Cites] Drug Saf. 2005;28(4):351-70 [15783243.001]
  • [Cites] Hepatology. 2000 Jan;31(1):201-6 [10613746.001]
  • [Cites] Eur J Clin Pharmacol. 2005 Apr;61(2):135-43 [15726344.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 9;97(10):5498-503 [10792025.001]
  • [Cites] Ann Intern Med. 2006 Mar 21;144(6):415-20 [16481451.001]
  • [Cites] Clin Pharmacol Ther. 2003 May;73(5):435-55 [12732844.001]
  • [Cites] Hepatology. 2002 Apr;35(4):883-9 [11915035.001]
  • [Cites] Gastroenterology. 1995 Jun;108(6):1849-54 [7768392.001]
  • [Cites] Ann Intern Med. 2002 Dec 17;137(12):947-54 [12484709.001]
  • [Cites] Hepatology. 2005 Aug;42(2):481-9 [16025496.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):512-21 [16083708.001]
  • [Cites] Cell Death Differ. 1999 Jun;6(6):516-24 [10381654.001]
  • [Cites] Hepatology. 2001 Jan;33(1):123-30 [11124828.001]
  • [Cites] Hepatology. 2006 Mar;43(3):618-31 [16496329.001]
  • [Cites] Hepatology. 2003 Apr;37(4):924-30 [12668988.001]
  • [Cites] Gastroenterology. 1999 Oct;117(4):962-71 [10500080.001]
  • [Cites] J Exp Med. 2000 Oct 2;192(7):921-30 [11015434.001]
  • [Cites] Hepatology. 1995 Sep;22(3):767-73 [7657281.001]
  • [Cites] Neurology. 2001 May 22;56(10 ):1405-9 [11376200.001]
  • [Cites] Gastroenterology. 1993 Jan;104(1):286-301 [8419252.001]
  • [Cites] Hepatology. 2005 May;41(5):1179-97 [15841455.001]
  • [Cites] Toxicol Appl Pharmacol. 1995 Jul;133(1):43-52 [7597709.001]
  • [Cites] Dig Dis. 1994 Jul-Aug;12(4):191-8 [7850998.001]
  • [Cites] Hepatology. 2004 Jul;40(1):10-5 [15239079.001]
  • [Cites] J Hepatol. 1990 Sep;11(2):272-6 [2254635.001]
  • [Cites] Gastroenterology. 1996 Sep;111(3):716-9 [8780577.001]
  • [Cites] Clin Liver Dis. 2003 May;7(2):351-67 [12879988.001]
  • [Cites] Hepatology. 2001 Nov;34(5):964-71 [11679967.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):39-47 [10728793.001]
  • [Cites] J Biol Chem. 2001 Jul 6;276(27):24453-6 [11356822.001]
  • [Cites] J Hepatol. 1997;26 Suppl 2:37-42 [9204408.001]
  • [Cites] Chest. 1991 Feb;99(2):465-71 [1824929.001]
  • [Cites] Clin Liver Dis. 2000 Feb;4(1):73-96, vi [11232192.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1541-51 [9834283.001]
  • [Cites] Hepatology. 1998 Apr;27(4):1021-9 [9537442.001]
  • [Cites] Mol Pharmacol. 2001 Mar;59(3):627-35 [11179459.001]
  • [Cites] Clin Pharmacol Ther. 2001 Apr;69(4):223-31 [11309550.001]
  • [Cites] Immunol Rev. 2000 Apr;174:63-76 [10807507.001]
  • [Cites] Nature. 1999 Feb 4;397(6718):441-6 [9989411.001]
  • [Cites] Science. 1998 Aug 28;281(5381):1305-8 [9721089.001]
  • [Cites] Ann Intern Med. 1984 Apr;100(4):495-9 [6230976.001]
  • [Cites] Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1871-6 [9620920.001]
  • [Cites] Nat Rev Drug Discov. 2005 Jun;4(6):489-99 [15931258.001]
  • [Cites] J Clin Epidemiol. 1993 Nov;46(11):1323-30 [8229110.001]
  • [Cites] Am J Cardiol. 2000 Jun 22;85(12A):15E-9E [10858489.001]
  • [Cites] J Exp Med. 1997 Apr 21;185(8):1481-6 [9126928.001]
  • (PMID = 17408305.001).
  • [ISSN] 0114-5916
  • [Journal-full-title] Drug safety
  • [ISO-abbreviation] Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Pharmaceutical Preparations
  • [Number-of-references] 126
  •  go-up   go-down


42. Rozga J: Liver support technology--an update. Xenotransplantation; 2006 Sep;13(5):380-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver support technology--an update.
  • BACKGROUND: Currently, there is no direct treatment for hepatic failure, and patients must receive a transplant or endure prolonged hospitalization, with significant morbidity and mortality.
  • Because of the scarcity of donor organs, liver support strategies are being developed with the aim of either supporting patients with borderline functional liver cell mass until an appropriate organ becomes available for transplantation or until their livers recover from injury.
  • RESULTS: Currently, a number of blood purification systems and devices utilizing viable liver cells are in various stages of clinical development.
  • These systems are able to remove toxins of hepatic failure, and their utility is limited by their inability to provide missing liver-specific functions.
  • In contrast, hepatocyte-based devices are able to provide whole liver functions, including detoxification, biosynthesis, and biotransformation.
  • Molecular adsorbent recycling system (MARS) blood detoxification system has been tested in thousands of patients, but additional well-conducted controlled studies are warranted to better define the role of MARS in the treatment of patients with acute hepatic failure and acute exacerbation of chronic liver disease.
  • HepatAssist was tested in a phase II/III controlled clinical trial that demonstrated safety and proof of concept for use of biological liver support systems to improve patient survival in acute hepatic failure.
  • CONCLUSIONS: Developing an effective liver assist technology has proven difficult, because of the complexity of liver functions that must be replaced, as well as heterogeneity of the patient population.
  • Non-biological systems may have a role in the treatment of specific forms of liver failure where the primary goal is to provide blood detoxification/purification.
  • Biological systems appear to be useful in treating liver failure where the primary objective is to provide whole liver functions which are impaired or lost.
  • It is suggested that there will be a role for hybrid liver support systems that offer liver cell therapy and various forms of blood purification (sorption, hemofiltration and diafiltration) to treat patients with specific forms of liver failure at various stages of their illness.
  • [MeSH-major] Liver Failure, Acute / therapy. Liver, Artificial
  • [MeSH-minor] Animals. Hemodiafiltration / methods. Hepatocytes / metabolism. Humans. Liver Transplantation. Renal Dialysis / methods. Sorption Detoxification / methods. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925661.001).
  • [ISSN] 0908-665X
  • [Journal-full-title] Xenotransplantation
  • [ISO-abbreviation] Xenotransplantation
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 67
  •  go-up   go-down


43. Machado MA, Makdissi FF, Surjan RC, Kappaz GT, Yamaguchi N: Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis. Surg Endosc; 2010 Aug;24(8):2044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two-stage laparoscopic liver resection for bilateral colorectal liver metastasis.
  • BACKGROUND: Hepatectomy may prolong the survival of colorectal cancer patients with liver metastases.
  • Two-stage liver surgery is a valid option for the treatment of bilobar colorectal liver metastasis.
  • This video demonstrates technical aspects of a two-stage pure laparoscopic hepatectomy for bilateral liver metastasis.
  • To the authors' knowledge, this is the first description of a two-stage laparoscopic liver resection in the English literature.
  • METHODS: A 54-year-old man with right colon cancer and synchronous bilobar colorectal liver metastasis underwent laparoscopic right colon resection followed by oxaliplatin-based chemotherapy.
  • The patient then was referred for surgical treatment of liver metastasis.
  • Liver volumetry showed a small left liver remnant.
  • Surgical planning was for a totally laparoscopic two-stage liver resection.
  • The postoperative pathology showed high-grade liver steatosis.
  • After 4 weeks, the left liver had regenerated, and volumetry of left liver was 43%.
  • The line of liver transection was marked following the ischemic area.
  • Liver transection was accomplished with the Harmonic scalpel and an endoscopic stapling device.
  • The falciform ligament was fixed to maintain the left liver in its original anatomic position, avoiding hepatic vein kinking and outflow syndrome.
  • CONCLUSION: Two-stage liver resections can be performed safely using laparoscopy.
  • The intrahepatic Glissonian approach is a useful tool for pedicle control of the right liver, especially after previous dissection of the hilar plate.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy / methods. Laparoscopy. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Sep;246(3):385-92; discussion 392-4 [17717442.001]
  • [Cites] Br J Surg. 2005 May;92(5):592-5 [15779074.001]
  • [Cites] Ann Surg. 2008 Dec;248(6):994-1005 [19092344.001]
  • [Cites] Am J Surg. 2009 Jun;197(6):737-9 [18789420.001]
  • [Cites] Br J Surg. 1999 Jun;86(6):784-8 [10383579.001]
  • [Cites] Am J Surg. 2008 Oct;196(4):e38-42 [18614140.001]
  • [Cites] Am J Surg. 2009 Aug;198(2):173-7 [19268902.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2005 Jun;15(3):180-3 [15956908.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2009 Jun;19(3):409-13 [19215213.001]
  • [Cites] Arch Surg. 2003 Aug;138(8):918-20 [12912755.001]
  • [Cites] Arch Surg. 2008 Oct;143(10):978-82; discussion 982 [18936377.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51 [15570209.001]
  • [Cites] Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21 [10493478.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):818-25; discussion 825-7 [15166961.001]
  • [Cites] J Am Coll Surg. 2003 Jul;197(1):164-70 [12831938.001]
  • (PMID = 20108150.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Reuben A: Alcohol and the liver. Curr Opin Gastroenterol; 2006 May;22(3):263-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alcohol and the liver.
  • PURPOSE OF REVIEW: To apprise the reader of advances in 2005 in the epidemiology, pathogenesis, prognosis and treatment of alcoholic liver disease.
  • Alcohol use has declined in developed countries, but the opposite is true elsewhere; alcoholic liver disease is a considerable burden worldwide.
  • RECENT FINDINGS: Genetic mechanisms for alcoholic liver disease are being discovered in addition to aggravating cofactors, such as hepatitis C, obesity and iron overload, and ameliorating ones, like coffee and tea drinking.
  • The involvement of the innate immune system and the mechanisms of apoptosis in alcoholic liver disease are better appreciated, especially the emerging role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
  • Steroid use and nutrition for alcoholic hepatitis are being refined, and the validity of the model for end-stage liver disease (MELD) score in predicting the outcome of alcoholic liver disease is upheld.
  • Recidivism after liver transplantation for alcoholic liver disease adversely impacts long-term survival.
  • SUMMARY: Inroads are being made into the genetics of alcoholic liver disease and new phenomena are being uncovered in its pathogenesis, but safe and effective therapies for both alcoholic hepatitis and alcoholic cirrhosis are still wanting.
  • [MeSH-major] Liver Diseases, Alcoholic / etiology. Liver Diseases, Alcoholic / physiopathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550041.001).
  • [ISSN] 0267-1379
  • [Journal-full-title] Current opinion in gastroenterology
  • [ISO-abbreviation] Curr. Opin. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


45. Bouchnak M, Souissi K, Ouragini H, Abbes Z, Douiri H, Maghrebi H: [Maternal benefit of postpartum corticosteroid therapy in patients with HELLP (hemolysis elevated liver enzymes low platelets count) syndrome]. Tunis Med; 2005 Aug;83(8):473-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Maternal benefit of postpartum corticosteroid therapy in patients with HELLP (hemolysis elevated liver enzymes low platelets count) syndrome].
  • [Transliterated title] Intérêt de la corticothérapie en post partum dans le HELLP (hemolysis elevated liver enzymes low platelets count) syndrome.
  • Our purpose was to assess the effects of corticotherapy prescribed after delivery on the kinetic of biological parameters of HELLP syndrome (hemolysis elevated liver enzymes low platelets count).
  • The kinetic of the hepatic cytolysis marker was not modified by corticotherapy.

  • Genetic Alliance. consumer health - HELLP syndrome.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16238275.001).
  • [ISSN] 0041-4131
  • [Journal-full-title] La Tunisie médicale
  • [ISO-abbreviation] Tunis Med
  • [Language] fre
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Randomized Controlled Trial
  • [Publication-country] Tunisia
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Placebos; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


46. Wasmuth HE, Trautwein C: [Liver fibrosis : clinics, diagnostics and management]. Internist (Berl); 2010 Jan;51(1):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver fibrosis : clinics, diagnostics and management].
  • Liver fibrosis results from chronic liver damage and is characterized by scarring of the liver parenchyma.
  • Liver fibrosis can occur in all chronic liver diseases and shows progression towards liver cirrhosis in 20-40% of cases.
  • The clinical presentation of liver fibrosis is usually unspecific.
  • Therefore, most patients with liver fibrosis are identified by elevated liver enzymes during other medical examinations.
  • The gold standard for quantification of liver fibrosis is percutaneous liver biopsy, but non-invasive markers (e. g. serum markers, transient elastography) have recently been evaluated to identify individuals with significant fibrosis.
  • In case of fibrosis detection, medical therapies aim at stabilizing liver scarring or even at inducing the regression of fibrosis.
  • Primarily this is achieved by etiology specific therapies of chronic liver diseases (e. g. antiviral therapy, immunosuppressive therapy etc.).
  • [MeSH-major] Immunosuppressive Agents / therapeutic use. Liver Cirrhosis / diagnosis. Liver Cirrhosis / drug therapy

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2008 Sep;135(3):821-9 [18593587.001]
  • [Cites] Hepatology. 2007 Mar;45(3):569-78 [17326152.001]
  • [Cites] Gastroenterology. 2009 Jul;137(1):309-19, 319.e1-3 [19344719.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):1022 [12297856.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] World J Gastroenterol. 2009 Mar 28;15(12):1409-14 [19322911.001]
  • [Cites] Hepatology. 2007 Nov;46(5):1661-3 [17969048.001]
  • [Cites] Hepatology. 2003 Oct;38(4):859-68 [14512873.001]
  • [Cites] BMC Gastroenterol. 2007 Oct 15;7:40 [17937811.001]
  • [Cites] Hepatology. 2008 Aug;48(2):418-31 [18563841.001]
  • [Cites] J Hepatol. 2003 Aug;39(2):239-44 [12873821.001]
  • [Cites] J Hepatol. 2008 Apr;48(4):606-13 [18222014.001]
  • [Cites] N Engl J Med. 2006 Nov 30;355(22):2297-307 [17135584.001]
  • [Cites] Gastroenterology. 2008 May;134(6):1670-81 [18471546.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):598-607 [17692984.001]
  • [Cites] Hepatology. 2008 Mar;47(3):789-98 [18175357.001]
  • [Cites] J Hepatol. 2008 May;48(5):835-47 [18334275.001]
  • [Cites] Hepatology. 2007 Sep;46(3):912-21 [17705266.001]
  • [Cites] Hepatology. 2008 Feb;47(2):592-5 [18098325.001]
  • [Cites] Hepatology. 2006 Aug;44(2):472-7 [16871557.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):257-65 [12586290.001]
  • [Cites] N Engl J Med. 2008 Dec 4;359(23 ):2429-41 [19052125.001]
  • [Cites] Gastroenterology. 2004 Dec;127(6):1704-13 [15578508.001]
  • (PMID = 19921111.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


47. Cherqui D, Laurent A, Mocellin N, Tayar C, Luciani A, Van Nhieu JT, Decaens T, Hurtova M, Memeo R, Mallat A, Duvoux C: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg; 2009 Nov;250(5):738-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation.
  • BACKGROUND/PURPOSE: Liver transplantation (LT) is the best theoretical treatment of hepatocellular carcinoma (HCC) fulfilling the Milan criteria (TNM stages 1-2).
  • However, LT is limited by organ availability and tumor progression on the waiting list.
  • Liver resection (LR) may represent an alternative in these patients.
  • PATIENTS: From 1990 to 2007, 274 patients underwent liver resection for HCC.
  • Ten were TNM stage 1 and 57 stage 2 and all had chronic liver disease.
  • After a mean follow-up of 4.8 years, 36 patients (54%) developed intrahepatic tumor recurrence.
  • Survival was not influenced by TNM stage 1 or 2, AFP level, tumor differentiation, or the presence microscopic vascular invasion.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Hepatitis / complications. Hepatitis C / complications. Humans. Liver Cirrhosis, Alcoholic / complications. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


48. Montalvo-Jave EE, Villegas-Alvarez F, Montalvo-Arenas CE, Peña-Sánchez J, Gutiérrez-Vega R, Piña E: Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review. Rev Gastroenterol Mex; 2009 Oct-Dec;74(4):341-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation: some advances in liver cancer, live liver donation, and cell transplantation. A literature review.
  • Liver transplantation constitutes a constant challenge in finding viable options to maintain or recover an adequate function when faced with end-stage liver failure.
  • Critical review of the literature was conducted in specific topics on liver transplantation and development in Mexico.
  • We focused our review on medical and surgical topics such as liver procurement from a related living donor, liver transplantation options for patients with liver cancer, especially hepatocellular carcinoma and cholangiocarcinoma, as well as on cellular and molecular biology aspects, such as xenotransplantation and hepatocyte transplantation.
  • [MeSH-major] Cell Transplantation. Liver Neoplasms / surgery. Liver Transplantation. Tissue and Organ Procurement


49. Bueno J, Escartín A, Balsells J, Margarit C: Intraoperative flow measurement of native liver and allograft during orthotopic liver transplantation in children. Transplant Proc; 2007 Sep;39(7):2278-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative flow measurement of native liver and allograft during orthotopic liver transplantation in children.
  • Hepatic hemodynamic changes during liver transplantation (OLT) in children have not yet been studied.
  • We measured intraoperative portal vein flow (PVF) and hepatic arterial flow (HAF) (mL/min) in 53 children and 58 grafts during OLT.
  • In the native liver, PVF and HAF are similar; after transplantation they return to the physiological situation.
  • Among the 8 (14%) portal vein thromboses, PVF was lower in both the native liver and the graft than in the no thrombosis group (P < .05).
  • [MeSH-major] Liver Circulation. Liver Transplantation. Monitoring, Intraoperative
  • [MeSH-minor] Blood Flow Velocity. Child. Hepatic Artery / physiology. Humans. Portal Vein / physiology. Thrombosis / diagnosis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17889162.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Song CH, Chen LM, Zhang LX: [Analysis of the result of 409 cases with liver cirrhosis and severe hepatitis by using the model for end-stage liver disease]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun;21(2):168-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the result of 409 cases with liver cirrhosis and severe hepatitis by using the model for end-stage liver disease].
  • OBJECTIVE: To analyze the influence of the model for end-stage liver disease (MELD) results in 409 cases with liver cirrhosis and severe hepatitis and compare with Child-Pugh scoring system.
  • METHODS: The data of 409 patients with liver cirrhosis and severe hepatitis were collected and analyzed by using the Child-Pugh and MELD scoring systems, and Chiss statistical software was applied.
  • CONCLUSION: The changes in total serum bilirubin and creatinine can influence the result significantly, not the INR, and a better way to predict the prognosis of severe liver disease may be application of MELD combined with clinical experience.
  • [MeSH-major] Hepatitis / diagnosis. Liver Cirrhosis / diagnosis. Liver Failure / diagnosis

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis Testing.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653326.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] AYI8EX34EU / Creatinine; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


56. Barshes NR, Lee TC, Udell IW, O'mahoney CA, Karpen SJ, Carter BA, Goss JA: The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients. Liver Transpl; 2006 Mar;12(3):475-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pediatric end-stage liver disease (PELD) model as a predictor of survival benefit and posttransplant survival in pediatric liver transplant recipients.
  • The pediatric end-stage liver disease (PELD) model accurately estimates 90-day waitlist mortality for pediatric liver transplant candidates, but it has been unclear if PELD can identify patients who will derive survival benefit from undergoing liver transplantation (LT), if it correlates with posttransplant survival, or if it can identify patients for whom LT would be futile.
  • Complete data were available for 1,247 patients: 53% were listed as Status 1 at the time of orthotopic liver transplantation (OLT), while the remaining 47% had PELD scores.
  • In conclusion, pediatric patients with a PELD score of 17+ derive survival benefit early after LT, and increasing PELD scores are associated with increasing transplant benefit after liver transplantation.
  • [MeSH-major] Algorithms. Cause of Death. Liver Failure / mortality. Liver Transplantation / mortality. Postoperative Complications / mortality. Tissue and Organ Procurement

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 AASLD
  • (PMID = 16498644.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Hervé J, Cunha AS, Liu B, Valogne Y, Longuet M, Boisgard R, Brégerie O, Roux J, Guettier C, Calès P, Tavitian B, Samuel D, Clerc J, Bréchot C, Faivre J: Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter. Hum Gene Ther; 2008 Sep;19(9):915-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Internal radiotherapy of liver cancer with rat hepatocarcinoma-intestine-pancreas gene as a liver tumor-specific promoter.
  • The hepatocarcinoma-intestine-pancreas (HIP) gene, also called pancreatitis-associated protein-1 (PAP1) or Reg IIIalpha, is activated in most human hepatocellular carcinomas (HCCs) but not in normal liver, which suggests that HIP regulatory sequence could be used as efficient liver tumor-specific promoters to express a therapeutic polynucleotide in liver cancer.
  • For this purpose, we constructed a recombinant rat HIP-NIS adenoviral vector (AdrHIP-NIS), and evaluated its performance as a mediator of selective radioiodide uptake in tumor hepatocytes.
  • Western blot, immunofluorescence, and iodide uptake assays were performed in AdrHIP-NIS-infected primary hepatocytes and transformed hepatic and nonhepatic cells.
  • Nuclear imaging, tissue counting and immunohistochemistry were performed in normal and HCC-bearing Wistar rats infected with AdrHIP-NIS intratumorally or via the hepatic artery.
  • In AdrHIP-NIS-infected transformed hepatic cells, functional NIS was strongly expressed, as in cells infected with a cytomegalovirus-NIS vector.
  • In rats bearing multinodular HCC, AdrHIP-NIS triggered functional NIS expression that was preferential in tumor hepatocytes.
  • This study has identified the rHIP regulatory sequence as a potent liver tumor-specific promoter for the transfer of therapeutic genes, and AdrHIP-NIS-mediated (131)I therapy as a valuable option for the treatment of multinodular HCC.
  • [MeSH-major] Antigens, Neoplasm / genetics. Biomarkers, Tumor / genetics. Lectins, C-Type / genetics. Liver Neoplasms, Experimental / radiotherapy. Liver Neoplasms, Experimental / therapy
  • [MeSH-minor] Adenoviridae / genetics. Animals. Base Sequence. Cell Line. Cell Line, Tumor. DNA, Recombinant / genetics. Dogs. Female. Gene Expression. Gene Transfer Techniques. Genetic Vectors. Humans. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / therapeutic use. Male. Promoter Regions, Genetic. Rats. Rats, Wistar. Symporters / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18759560.001).
  • [ISSN] 1557-7422
  • [Journal-full-title] Human gene therapy
  • [ISO-abbreviation] Hum. Gene Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Recombinant; 0 / Iodine Radioisotopes; 0 / Lectins, C-Type; 0 / Symporters; 0 / pancreatitis-associated protein; 0 / sodium-iodide symporter
  •  go-up   go-down


58. Lordan JT, Worthington TR, Quiney N, Fawcett W, Karanjia ND: Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients. HPB (Oxford); 2009 Jun;11(4):321-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early postoperative outcomes following hepatic resection for benign liver disease in 79 consecutive patients.
  • BACKGROUND: Liver resection is an accepted treatment modality for malignant disease of the liver.
  • However, because of its potential morbidity and mortality, the practice of liver resection in benign disease is more controversial.
  • This study was designed to assess the early outcomes of 79 consecutive liver resections for benign disease over a 12-year period and compare these with early outcomes of 390 consecutive liver resections for metastatic colorectal cancer (MCRC) during the same period.
  • METHODS: Consecutive liver resections were carried out in a single hepatopancreatobiliary (HPB) centre between 1996 and 2008.
  • RESULTS: There was no difference in median age between the benign group vs. the MCRC group (P = 0.181).
  • However, there was a significant trend towards a lower ASA grade in the benign group (P < 0.001).
  • Morbidity rates were 8.9% in the benign group and 20.5% in the MCRC group (P = 0.002).
  • The rate of serious complications was 1.3% in the benign group compared with 4.4% in the MCRC group (P = 0.041).
  • There were no postoperative deaths in the benign group and eight (2%) in the MCRC group (P = 0.004).
  • CONCLUSIONS: Liver resection for benign liver tumours can be undertaken with a mortality rate approaching zero and minimal morbidity in specialist HPB units.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2009 Mar;35(3):302-6 [18328668.001]
  • [Cites] J Am Coll Surg. 2000 Jul;191(1):38-46 [10898182.001]
  • [Cites] Am J Surg. 2007 Jan;193(1):5-9 [17188079.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1192-201 [16983740.001]
  • [Cites] Int J Clin Oncol. 2005 Apr;10(2):86-96 [15864693.001]
  • [Cites] BMC Surg. 2005;5:5 [15774004.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):13-8 [7740799.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):190-5 [2840865.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Br J Cancer. 1976 Dec;34(6):585-612 [795448.001]
  • [Cites] Ann Surg. 2004 Aug;240(2):205-13 [15273542.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1033-8 [11529826.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):808-13 [11412249.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):1007-16 [18358928.001]
  • (PMID = 19718359.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2727085
  • [Keywords] NOTNLM ; benign liver disease / liver resection
  •  go-up   go-down


59. Ritchie AH, Williscroft DM: Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature. Can J Rural Med; 2006;11(4):283-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated liver enzymes as a predictor of liver injury in stable blunt abdominal trauma patients: case report and systematic review of the literature.
  • Liver injury secondary to blunt abdominal trauma is a well-defined entity in emergency medicine.
  • A challenge exists in the diagnosis of liver trauma in the stable, wellappearing patient with a history of blunt abdominal trauma.
  • In centres lacking advanced diagnostic modalities an elevation in hepatic transaminases may provide guidance for the rural emergency physician in seeking further imaging and/or surgical consultation.
  • There appears to be a direct relationship between blunt liver trauma and elevation in liver transaminases.
  • [MeSH-major] Abdominal Injuries / blood. Liver / injuries. Transaminases / blood. Wounds, Nonpenetrating / diagnosis
  • [MeSH-minor] Adult. Humans. Liver Function Tests. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054829.001).
  • [ISSN] 1203-7796
  • [Journal-full-title] Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la médecine rurale : le journal officiel de la Société de médecine rurale du Canada
  • [ISO-abbreviation] Can J Rural Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] EC 2.6.1.- / Transaminases
  • [Number-of-references] 27
  •  go-up   go-down


60. Barreiros AP, Post F, Hoppe-Lotichius M, Linke RP, Vahl CF, Schäfers HJ, Galle PR, Otto G: Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience. Liver Transpl; 2010 Mar;16(3):314-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation and combined liver-heart transplantation in patients with familial amyloid polyneuropathy: a single-center experience.
  • Liver transplantation (LT) is the only curative option for patients with familial amyloid polyneuropathy (FAP) at present.
  • Seven patients received a pacemaker prior to LT, and because of impairment of mechanical cardiac function, 4 combined heart-liver transplants were performed, 1 simultaneously and 3 sequentially.
  • Cardiac symptoms occurred predominantly in patients with non-Val30Met mutations and prompted combined heart-liver transplantation in 4 patients.
  • Combined heart-liver transplantation should be considered in patients with restrictive cardiomyopathy.
  • [MeSH-major] Amyloid Neuropathies, Familial / surgery. Heart Transplantation. Liver Transplantation


61. Lau WY, Lai EC: Hepatic resection for colorectal liver metastases. Singapore Med J; 2007 Jul;48(7):635-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic resection for colorectal liver metastases.
  • INTRODUCTION: Nearly 50 percent of patients who have colorectal carcinoma will develop liver metastases, which is frequently the cause of death.
  • Liver resection is the only curative treatment for patients with colorectal metastases confined to the liver.
  • However, liver resection can be performed in only ten percent of patients.
  • A strategy to improve resectability and outcome of patients with colorectal liver metastases is needed.
  • METHODS: The progress and outcome of patients, who had colorectal liver metastases and underwent liver resection in a tertiary surgical centre between January 1998 and December 2002, were retrospectively studied.
  • RESULTS: During the five-year study period, 42 patients with colorectal liver metastasis underwent hepatic resection.
  • 36 patients received primary liver resection.
  • Six patients with initially unresectable disease received salvage surgery after tumour downstaging with systemic chemotherapy.
  • Five of the 42 patients needed repeat liver resection for recurrent colorectal liver metastases.
  • The five-year survival rate with salvage surgery after tumour downstaging was 34 percent, and the corresponding figure, after repeat liver resection, for recurrent liver metastases was 27 percent.
  • CONCLUSION: Hepatic resection for colorectal metastases confined to the liver resulted in reasonably good long-term survival, with acceptably low operative mortality and morbidity.
  • Our results were compatible with the international standard of liver resection for colorectal liver metastases.
  • [MeSH-major] Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609825.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


62. Petri A, Höhn J, Kókai EL, Savanya GK, Lázár G: Surgery of benign liver tumors: indications for treatment: twenty years' experience. Hepatogastroenterology; 2008 Mar-Apr;55(82-83):592-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgery of benign liver tumors: indications for treatment: twenty years' experience.
  • METHODOLOGY: Between January 1982 and December 2001, 132 patients with benign liver tumor (adenoma: 22; focal nodular hyperplasia: 27; hemangioma: 83) were treated.
  • The mean age, the female/male ratio and the size of the tumor in the adenoma cases were 38.2 years, 20/2 and 7.7cm, while for focal nodular hyperplasia they were 39.4, 24/3 and 6.3cm, and for hemangioma 49.0, 62/21 and 6.5cm.
  • RESULTS: Enucleation was performed in 45.4% of the patients, nonanatomical resection in 35.6%, segmentectomy in 7%, lobectomy in 3.8%, extended lobectomy in 1.5%, stitching in 4.5%, exploration in 2.3% and liver transplantation in 0.8%.
  • [MeSH-major] Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18613414.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


63. Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, Ahn JB, Roh JK, Noh SH, Chung HC: Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol; 2008 Jun;19(6):1146-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases.
  • BACKGROUND: The benefit of surgical resection of liver metastases from gastric cancer has not been well established.
  • The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer.
  • METHODS: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery.
  • RESULTS: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years.
  • The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival.
  • CONCLUSIONS: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved.
  • Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18304963.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


64. Steurer W: [Liver transplantation]. Praxis (Bern 1994); 2006 Sep 20;95(38):1465-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liver transplantation].
  • Liver transplantation has developed as standard therapy for end-stage liver disease and fulminant hepatic failure with excellent results.
  • The application of new techniques including split liver and living donor liver transplantation (LDLT) has only marginally increased the total number of liver transplants.
  • [MeSH-major] Liver Diseases / surgery. Liver Failure / surgery. Liver Neoplasms / surgery. Liver Transplantation


65. Iimuro Y, Brenner DA: Matrix metalloproteinase gene delivery for liver fibrosis. Pharm Res; 2008 Feb;25(2):249-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase gene delivery for liver fibrosis.
  • The resolution of advanced liver fibrosis has been recently recognized to be possible, if the causative stimuli are successfully removed.
  • However, whether complete resolution from cirrhosis, the end stage of liver fibrosis, can be achieved is still questionable.
  • Delivery of interstitial collagenases, such as matrix metalloproteinase (MMP)-1, in the liver could be an attractive strategy to treat advanced hepatic fibrosis from the view point that the imbalance between too few interstitial collagenases and too many of their inhibitors is the main obstacle to the resolution from fibrosis.
  • Remodeling of hepatic extracellular matrix by delivered interstitial collagenases also facilitates the disappearance of activated hepatic stellate cells, the main matrix-producing cells in the liver, and promotes the proliferation of hepatocytes.
  • This review will focus on the impact of the gene delivery of MMPs for the treatment of advanced liver fibrosis while discussing other current therapeutic strategies for liver fibrosis, and on the need for the development of a safe and effective delivery system of MMPs.
  • [MeSH-major] Genetic Therapy. Liver Cirrhosis / therapy. Matrix Metalloproteinases / genetics

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2004 Nov;40(5):1106-15 [15389776.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1151-9 [15389867.001]
  • [Cites] Am J Med. 1970 Nov;49:707-21 [4924592.001]
  • [Cites] N Engl J Med. 1988 Jun 30;318(26):1709-13 [3287167.001]
  • [Cites] Exp Pathol. 1988;34(4):229-36 [2853079.001]
  • [Cites] Gastroenterology. 1990 Jan;98(1):175-84 [2293576.001]
  • [Cites] J Clin Invest. 1989 Dec;84(6):1786-93 [2592560.001]
  • [Cites] Cell Mol Biol. 1990;36(2):131-53 [2165861.001]
  • [Cites] Hepatology. 1991 Feb;13(2):282-8 [1995439.001]
  • [Cites] J Clin Invest. 1992 Jul;90(1):282-7 [1634616.001]
  • [Cites] Hepatology. 1992 Oct;16(4):1014-21 [1398481.001]
  • [Cites] J Hepatol. 1992 Jul;15(3):336-44 [1447500.001]
  • [Cites] Semin Cell Biol. 1993 Jun;4(3):189-201 [7688595.001]
  • [Cites] Clin Chim Acta. 1993 Sep 17;218(1):47-58 [8299219.001]
  • [Cites] Am J Pathol. 1994 Mar;144(3):528-37 [8129038.001]
  • [Cites] J Biol Chem. 1994 Jun 17;269(24):16766-73 [8207000.001]
  • [Cites] Mol Cell Biol. 1994 Sep;14(9):5858-69 [8065319.001]
  • [Cites] Virchows Arch. 1994;424(1):25-31 [7981900.001]
  • [Cites] J Biochem. 1995 Sep;118(3):643-9 [8690730.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):821-31 [8608892.001]
  • [Cites] Gastroenterology. 1996 Jun;110(6):1847-53 [8964410.001]
  • [Cites] J Hepatol. 1996 Aug;25(2):200-5 [8878782.001]
  • [Cites] J Hepatol. 1996 Feb;24(2):238-45 [8907579.001]
  • [Cites] Am J Physiol. 1997 Jan;272(1 Pt 1):G116-23 [9038884.001]
  • [Cites] Gastroenterology. 1997 Apr;112(4):1297-306 [9098016.001]
  • [Cites] Alcohol Clin Exp Res. 1997 Apr;21(2):375-9 [9113278.001]
  • [Cites] Gut. 1997 Jan;40(1):133-8 [9155591.001]
  • [Cites] J Hepatol. 1997 Sep;27(3):554-61 [9314134.001]
  • [Cites] Gastroenterology. 1997 Oct;113(4):1069-73 [9322499.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1265-72 [9358752.001]
  • [Cites] Hepatology. 1997 Dec;26(6):1530-7 [9397994.001]
  • [Cites] Gastroenterology. 1998 Jan;114(1):139-52 [9428228.001]
  • [Cites] Hepatology. 1998 Mar;27(3):720-6 [9500700.001]
  • [Cites] J Hepatol. 1998 Apr;28(4):615-21 [9566830.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):538-49 [9691091.001]
  • [Cites] Hepatology. 1998 Dec;28(6):1525-31 [9828216.001]
  • [Cites] Am J Pathol. 1998 Dec;153(6):1895-902 [9846979.001]
  • [Cites] Dig Dis Sci. 1998 Dec;43(12):2573-6 [9881484.001]
  • [Cites] J Hepatol. 2006 Sep;45(3):429-38 [16846660.001]
  • [Cites] Hepatology. 2007 Jan;45(1):213-22 [17187438.001]
  • [Cites] J Biol Chem. 2002 Mar 29;277(13):11069-76 [11796725.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1525-8 [11984538.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):291-300 [12105857.001]
  • [Cites] World J Gastroenterol. 2002 Aug;8(4):739-45 [12174389.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):850-60 [12297832.001]
  • [Cites] Gene Ther. 2002 Dec;9(24):1647-52 [12457277.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):445-58 [12557150.001]
  • [Cites] Gastroenterology. 2003 Feb;124(2):504-20 [12557155.001]
  • [Cites] J Biol Chem. 2003 Mar 7;278(10):8083-90 [12502711.001]
  • [Cites] J Hepatol. 2003 Apr;38(4):468-75 [12663239.001]
  • [Cites] Liver Transpl. 2003 Apr;9(4):331-8 [12682882.001]
  • [Cites] Circ Res. 2003 May 2;92(8):827-39 [12730128.001]
  • [Cites] Gastroenterology. 1999 Feb;116(2):378-86 [9922319.001]
  • [Cites] Nat Med. 1999 Feb;5(2):226-30 [9930873.001]
  • [Cites] Hepatology. 1999 Oct;30(4):944-50 [10498646.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1304-11 [15565662.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):56-65 [15630444.001]
  • [Cites] Gastroenterology. 2005 Jan;128(1):108-20 [15633128.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2005 May;288(5):G907-13 [15618280.001]
  • [Cites] Annu Rev Biochem. 2005;74:711-38 [15952901.001]
  • [Cites] FASEB J. 2006 Mar;20(3):444-54 [16507762.001]
  • [Cites] Gastroenterology. 2006 May;130(6):1807-21 [16697743.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12719-24 [10535989.001]
  • [Cites] J Hepatol. 1999 Dec;31(6):1053-61 [10604579.001]
  • [Cites] J Hepatol. 1999 Dec;31(6):1120-30 [10604588.001]
  • [Cites] J Biol Chem. 2000 Jan 28;275(4):2247-50 [10644669.001]
  • [Cites] J Hepatol. 2000;32(1 Suppl):32-8 [10728792.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1149-56 [10833490.001]
  • [Cites] J Hepatol. 2000 May;32(5):762-70 [10845663.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G245-9 [10915630.001]
  • [Cites] Arch Pathol Lab Med. 2000 Nov;124(11):1599-607 [11079009.001]
  • [Cites] Mol Ther. 2000 Dec;2(6):545-51 [11124055.001]
  • [Cites] N Engl J Med. 2001 Feb 8;344(6):418-23 [11172178.001]
  • [Cites] Curr Top Pathol. 1999;93:205-18 [10339913.001]
  • [Cites] Gut. 2001 Apr;48(4):548-57 [11247901.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1784-800 [11375959.001]
  • [Cites] J Hepatol. 2001 May;34(5):764-7 [11434626.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):148-55 [11438504.001]
  • [Cites] J Biol Chem. 2001 Jul 27;276(30):28274-80 [11346654.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):685-98 [11522753.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):745-50 [11584371.001]
  • [Cites] Semin Liver Dis. 2001 Aug;21(3):437-51 [11586471.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):392-8 [11592601.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):40591-8 [11509553.001]
  • [Cites] J Hepatol. 2001 Oct;35(4):474-81 [11682031.001]
  • [Cites] Clin Liver Dis. 2001 Nov;5(4):1073-90 [11685796.001]
  • [Cites] Cochrane Database Syst Rev. 2001;(3):CD002148 [11687017.001]
  • [Cites] Front Biosci. 2002 Feb 1;7:d496-503 [11815289.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):178-91 [12851882.001]
  • [Cites] Br J Pharmacol. 2003 Jul;139(6):1085-94 [12871826.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2003 Sep;15(9):951-7 [12923366.001]
  • [Cites] Hepatology. 2003 Oct;38(4):859-68 [14512873.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1849-58 [14578185.001]
  • [Cites] Tissue Eng. 2003 Dec;9(6):1289-99 [14674437.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):955-63 [15057733.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1122-33; discussion 949 [15057751.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1646-54 [15084697.001]
  • [Cites] Hepatology. 2004 May;39(5):1390-7 [15122768.001]
  • [Cites] BMC Gastroenterol. 2003 Oct 18;3:29 [14565855.001]
  • [Cites] Lab Invest. 2004 Jun;84(6):766-77 [15077122.001]
  • [Cites] Gastroenterology. 2004 Jun;126(7):1795-808 [15188175.001]
  • [Cites] J Hepatol. 2004 Aug;41(2):235-41 [15288472.001]
  • [Cites] Hepatology. 1999 Mar;29(3):858-67 [10051490.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2345-9 [10051644.001]
  • (PMID = 17577645.001).
  • [ISSN] 0724-8741
  • [Journal-full-title] Pharmaceutical research
  • [ISO-abbreviation] Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; EC 3.4.24.- / Matrix Metalloproteinases
  • [Number-of-references] 105
  • [Other-IDs] NLM/ PMC2245995
  •  go-up   go-down


66. Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, Morteza A, Nakhjavani M: Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Metab Syndr; 2010;2:65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound.
  • BACKGROUND: Despite ongoing findings on the relationship between elevated levels of alanine and aspartate aminotransferases (ALT and AST) and metabolic syndrome (MetS), this association in diabetic patients without a known cause for liver enzymes elevation other than diabetes, per se, remains unclear.
  • In this study, we aimed to assess the relationship between circulating liver enzymes and MetS in a relatively large sample of patients with diabetes.
  • Patients with ultrasonographic signs of fatty liver disease were not included.
  • CONCLUSION: In diabetic patients without ultrasonographic evidence of fatty liver, elevated aminotransferases are independently associated with MetS.
  • Despite negative ultrasound results in diabetic patients with MetS, the serum level of liver aminotransferases may be elevated and should be more thoroughly monitored.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21047423.001).
  • [ISSN] 1758-5996
  • [Journal-full-title] Diabetology & metabolic syndrome
  • [ISO-abbreviation] Diabetol Metab Syndr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2987914
  •  go-up   go-down


67. Hanouneh IA, Zein NN: Metabolic syndrome and liver transplantation. Minerva Gastroenterol Dietol; 2010 Sep;56(3):297-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic syndrome and liver transplantation.
  • Non-alcoholic fatty liver disease (NAFLD), an important consequence of the global epidemic of obesity, is a common indication of orthotopic liver transplantation in the western world.
  • Currently, NAFLD is the fourth most common indication of liver transplantation in the United Stated with prediction for increase demand of liver transplantation for NAFLD cirrhosis in the next two decades to exceed that of liver transplantation for chronic hepatitis C virus infection.
  • Given the advances in the efficacy and tolerability of immunosuppressive agents which have reduced the incidence of chronic rejection, long-term survival rates after liver transplantation have remarkably improved.
  • Today, long-term graft loss and death after liver transplantation are commonly related to age-related complications, such as cardiovascular disease.
  • Features of metabolic syndrome including obesity, hypertension, hyperglycemia and dyslipidemia are very prevalent and almost universal after liver transplantation.
  • These metabolic derangements are intricately associated with cardiovascular events and have emerged as the leading cause of morbidity and mortality after liver transplantation.
  • In addition, the international epidemic of obesity has negatively impacted the liver transplant candidacy.
  • Because obesity is associated with poor postoperative outcome, many transplant centers decline liver transplantation for morbidly obese individuals above certain level of body mass index.
  • [MeSH-major] Liver Transplantation. Metabolic Syndrome X / complications. Postoperative Complications / etiology


68. Simpson N, Cho YW, Cicciarelli JC, Selby RR, Fong TL: Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database. Transplantation; 2006 Nov 27;82(10):1298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of renal allograft outcomes in combined liver-kidney transplantation versus subsequent kidney transplantation in liver transplant recipients: Analysis of UNOS Database.
  • BACKGROUND: There may be an allograft-enhancing effect by the liver on the renal allograft in the setting of simultaneous combined liver-kidney transplantation (CLKT) from the same donor.
  • This study was performed to investigate whether an existing liver allograft could protect a kidney allograft from immunologic injury due to histoincompatibility in liver transplant recipients who received sequential kidney transplantation (KALT).
  • CONCLUSION: Liver allograft provided renal graft immunoprotection if both organs are transplanted simultaneously (immunogenetic identity), but not for kidneys transplanted subsequently.
  • [MeSH-major] Graft Rejection / epidemiology. Graft Survival / physiology. Kidney Transplantation / physiology. Liver Transplantation / physiology. Tissue and Organ Procurement / statistics & numerical data


69. Boehnert MU, Hilbig H, Armbruster FP: Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver. Ann N Y Acad Sci; 2005 May;1041:434-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relaxin as an additional protective substance in preserving and reperfusion solution for liver transplantation, shown in a model of isolated perfused rat liver.
  • The study investigates the protective effect of relaxin on liver tissue against cell damage during organ preservation and reperfusion.
  • Liver transplantation was simulated in a model of isolated perfused rat liver.
  • To quantify cell damage, we examined the perfusate for malonyldialdehyde (MDA) and myeloperoxidase activity (MPO), and liver tissue underwent immunohistochemical study.
  • [MeSH-major] Liver / drug effects. Liver Transplantation / methods. Models, Animal. Organ Preservation / methods. Organ Preservation Solutions / chemistry. Relaxin / pharmacology. Reperfusion Injury / prevention & control

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15956742.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organ Preservation Solutions; 0 / Solutions; 4Y8F71G49Q / Malondialdehyde; 9002-69-1 / Relaxin
  •  go-up   go-down


70. von Oppen N, Schurich A, Hegenbarth S, Stabenow D, Tolba R, Weiskirchen R, Geerts A, Kolanus W, Knolle P, Diehl L: Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization. Hepatology; 2009 May;49(5):1664-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic antigen cross-presented by liver sinusoidal endothelial cells induces liver-specific CD8 T-cell retention and tolerization.
  • Peripheral CD8 T-cell tolerance can be generated outside lymphatic tissue in the liver, but the course of events leading to tolerogenic interaction of hepatic cell populations with circulating T-cells remain largely undefined.
  • Here we demonstrate that preferential uptake of systemically circulating antigen by murine liver sinusoidal endothelial cells (LSECs), and not by other antigen-presenting cells in the liver or spleen, leads to cross-presentation on major histocompatibility complex (MHC) I molecules, which causes rapid antigen-specific naïve CD8 T-cell retention in the liver but not in other organs.
  • [MeSH-major] Antigen Presentation. CD8-Positive T-Lymphocytes / immunology. Cross-Priming. Endothelial Cells / immunology. Liver / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205034.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 9006-59-1 / Ovalbumin
  •  go-up   go-down


71. Obach RS, Dobo KL: Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessment. Environ Mol Mutagen; 2008 Oct;49(8):631-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of metabolite profiles generated in Aroclor-induced rat liver and human liver subcellular fractions: considerations for in vitro genotoxicity hazard assessment.
  • Because it is well known that metabolites of chemicals and drugs are frequently the ultimate species responsible for genotoxicity and carcinogenicity, in vitro testing to identify the human genotoxicity hazard potential of new chemicals and drugs routinely utilizes liver S-9 fraction from rats treated with Aroclor 1254 as a system that can generate metabolites.
  • To address this, 16 common drugs have been examined for profiles of metabolites in Aroclor-induced rat liver S-9 and pooled human liver S-9.
  • These findings suggest that when conducting in vitro genotoxicity testing using the Aroclor-induced rat liver S-9 system, knowledge of the metabolite profile in the system is important, and a comparison to the profile generated in human liver S-9 could be of value when interpreting the genotoxicity results.
  • [MeSH-major] Aroclors / toxicity. Liver / drug effects. Mutagens / toxicity. Subcellular Fractions / drug effects


72. Rubio-Tapia A, Murray JA: The liver in celiac disease. Hepatology; 2007 Nov;46(5):1650-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The liver in celiac disease.
  • Celiac disease is a common (1% prevalence) chronic immune-mediated disorder of the small intestine induced by dietary wheat, barley, and rye.
  • Several hepatic disorders have been described in association with celiac disease.
  • Isolated hypertransaminasemia with nonspecific histologic changes in a liver biopsy is the commonest hepatic presentation of celiac disease.
  • A gluten-free diet normalizes liver enzymes and histologic changes in most patients.
  • Moreover, celiac disease can coexist with autoimmune liver disorders such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis.
  • Celiac disease has increasingly been reported with a variety of other liver diseases.
  • Thus, the hepatologist needs to consider celiac disease in the differential of abnormal liver blood tests and to be aware of the clinical implications of this frequent disease in patients with liver disorders.
  • The possible mechanisms of liver injury and those common factors that explain the association of celiac disease with liver disorders are discussed.
  • The aims of this article are (1) to review the spectrum and pathogenesis of liver injury related to celiac disease and (2) to provide direction to those caring for patients with chronic liver diseases regarding the detection and effective treatment of celiac disease.
  • [MeSH-major] Celiac Disease / complications. Liver Diseases / etiology
  • [MeSH-minor] Antibodies / blood. Cholangitis, Sclerosing / epidemiology. Cholangitis, Sclerosing / etiology. Cholangitis, Sclerosing / therapy. Gliadin / immunology. Hemochromatosis / complications. Humans. Liver Transplantation. Pancreatic Diseases / complications. Prevalence. Transglutaminases / immunology


73. Berends MA, van Oijen MG, Snoek J, van de Kerkhof PC, Drenth JP, Han van Krieken J, de Jong EM: Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol; 2007 Dec;143(12):1515-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens.
  • OBJECTIVE: To determine the interobserver reliability of the Roenigk score as a classification system of liver damage and its possible consequences for clinical practice.
  • Patients One hundred sixty liver biopsy specimens from patients with psoriasis receiving methotrexate treatment were rereviewed and analyzed blindly by an experienced pathologist with an interest in liver pathologic conditions.
  • Conclusion The Roenigk classification in the assessment of liver fibrosis is a reliable scoring system.
  • [MeSH-major] Dermatologic Agents / adverse effects. Drug-Induced Liver Injury. Liver Diseases / pathology. Methotrexate / adverse effects. Psoriasis / drug therapy. Severity of Illness Index
  • [MeSH-minor] Biopsy. Female. Humans. Liver / pathology. Male. Reproducibility of Results. Retrospective Studies. Single-Blind Method

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18087000.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dermatologic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


74. Richard M, Arfi A, Seguin J, Gandolphe C, Scherman D: Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery. Gene Ther; 2009 Jun;16(6):746-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery.
  • Using this animal model, we compared two plasmid gene administration techniques: muscle electrotransfer and liver-directed transfer using hydrodynamic injection.
  • The liver seemed to be more appropriate than the muscle as a target organ to enable enzyme secretion into the systemic circulation.
  • A beneficial effect on the MPS VII pathology was also observed, as liver-directed gene transfer led to the correction of secondary enzymatic elevations and to the reduction of GAGs storage in peripheral tissues and brain, as well as to histological correction in many tissues.
  • [MeSH-major] Gene Transfer Techniques. Glycoside Hydrolases / genetics. Glycoside Hydrolases / metabolism. Liver / metabolism. Mucopolysaccharidosis VII / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357715.001).
  • [ISSN] 1476-5462
  • [Journal-full-title] Gene therapy
  • [ISO-abbreviation] Gene Ther.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Glycosaminoglycans; 0 / RNA, Messenger; EC 3.2.1.- / Glycoside Hydrolases
  •  go-up   go-down


75. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK, Yuen MF: Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int; 2008 Dec;28(10):1408-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis.
  • Abstract Aim: To correlate liver stiffness with demographical factors and routine liver biochemistry and to assess the predictive value of these as potential markers of fibrosis.
  • According to a previous validated study for CHB, liver stiffness of >8.1 and >10.3 kPa were used as cut-off values for defining severe fibrosis and cirrhosis respectively.
  • RESULTS: Liver stiffness correlated positively with bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), aspartate aminotransferase (AST), alanine aminotransferase (ALT), globulin, alpha-fetoprotein (AFP) and HBV DNA levels and negatively with albumin and platelet levels (P<0.05 for all correlations).
  • From 13 parameters (age, sex, platelet, AST, ALT, GGT, AFP, albumin, globulin, bilirubin, ALP, HBV DNA and hepatitis B e-antigen), four best parameters (AST, platelet, GGT and AFP) were used to derive a liver stiffness model.
  • CONCLUSION: Routine liver biochemistry correlated well with liver stiffness in Asian CHB patients.
  • A model using simple serum markers can predict liver stiffness, and further studies are required to validate the usefulness of these simple tests as non-invasive markers of fibrosis in CHB.
  • [MeSH-major] Hepatitis B, Chronic / pathology. Liver / metabolism. Liver Cirrhosis / diagnosis. Models, Biological

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18482268.001).
  • [ISSN] 1478-3231
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Globulins; 0 / alpha-Fetoproteins; EC 2.3.2.2 / gamma-Glutamyltransferase; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; EC 3.1.3.1 / Alkaline Phosphatase; RFM9X3LJ49 / Bilirubin
  •  go-up   go-down


76. Yamskova VP, Borisenko AV, Krasnov MS, Il'ina AP, Rybakova EY, Malcev DI, Yamskov IA: Effect of bioregulators isolated from the liver, blood serum, and bile of mammals on the state of newt liver tissue in organotypic culture. Bull Exp Biol Med; 2010 Dec;150(1):140-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of bioregulators isolated from the liver, blood serum, and bile of mammals on the state of newt liver tissue in organotypic culture.
  • We developed models of in vitro organotypic culturing of newt liver tissue with and without adhesion to the substrate.
  • The effects of bioregulators isolated from mammalian liver, blood serum, and bile were studied on the developed models and their specificity was demonstrated.
  • The state of the liver was evaluated by the area of clusters of pigmented cells and by the number of mitoses in the connective tissue cells of the cortical layer.
  • These bioregulators exhibited their biological effects only under conditions of roller organotypic culturing of newt liver tissue.
  • [MeSH-major] Bile / chemistry. Growth Substances / isolation & purification. Growth Substances / pharmacology. Liver / chemistry. Liver / cytology. Organ Culture Techniques / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21161073.001).
  • [ISSN] 1573-8221
  • [Journal-full-title] Bulletin of experimental biology and medicine
  • [ISO-abbreviation] Bull. Exp. Biol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Growth Substances
  •  go-up   go-down


77. Al Hamad AA, Hassanain M, Michel RP, Metrakos P, Roberge D: Stereotactic radiotherapy of the liver: a bridge to transplantation stereotactic radiotherapy of the liver: a bridge to transplantation. Technol Cancer Res Treat; 2009 Dec;8(6):401-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic radiotherapy of the liver: a bridge to transplantation stereotactic radiotherapy of the liver: a bridge to transplantation.
  • In North America, liver transplantation is one of the most commonly used curative therapies.
  • We present the case of 60-years old male diagnosed with HCC and awaiting liver transplantation.
  • Due to his vascular anatomy and tumor location, he was not a candidate for more standard local ablative therapies.
  • He was thus offered stereotactic radiotherapy as a bridge to liver transplantation.
  • Following transplant, 13 months later, pathological examination of the liver explant revealed only scarring at the site of radiation.
  • This case illustrated the fact that hepatic stereotactic radiotherapy is a promising and safe treatment for patients with HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / surgery. Liver Neoplasms / therapy. Liver Transplantation / methods. Radiosurgery / methods
  • [MeSH-minor] Case-Control Studies. Humans. Liver Cirrhosis, Alcoholic / therapy. Male. Middle Aged. Radiometry. Time Factors. Tomography, X-Ray Computed / methods. Treatment Outcome. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19925023.001).
  • [ISSN] 1533-0338
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


78. Shames BD, Fernandez LA, Sollinger HW, Chin LT, D'Alessandro AM, Knechtle SJ, Lucey MR, Hafez R, Musat AI, Kalayoglu M: Liver transplantation for HELLP syndrome. Liver Transpl; 2005 Feb;11(2):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for HELLP syndrome.
  • Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome is a rare complication of pregnancy that is associated with preeclampsia and may result in rupture of the liver.
  • Although there have been case reports of liver transplantation for HELLP syndrome, the outcomes of transplantation for this rare indication have not been reported.
  • Furthermore, the optimal management of complicated HELLP syndrome and indications for liver transplantation are unclear.
  • Our objective was to review the national experience with liver transplantation for HELLP syndrome and to develop a comprehensive algorithm for the management of liver complications of HELLP syndrome, including indications for transplantation.
  • The results of liver transplantation for HELLP syndrome were analyzed from the United Network for Organ Sharing database.
  • Between October 1987 and November 2003 there have been 8 deceased donor liver transplants performed for complications related to HELLP syndrome.
  • This review supports that good results can be obtained with liver transplantation for patients with complicated HELLP syndrome that have either ongoing, uncontrolled hemorrhage or liver necrosis and failure.
  • Patients with complicated HELLP syndrome are best managed at a center with expertise in liver transplantation.
  • [MeSH-major] HELLP Syndrome / surgery. Liver Diseases / surgery. Liver Transplantation. Pregnancy Outcome


79. Nobili V, Alkhouri N, Bartuli A, Manco M, Lopez R, Alisi A, Feldstein AE: Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease. Pediatr Res; 2010 Jun;67(6):665-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severity of liver injury and atherogenic lipid profile in children with nonalcoholic fatty liver disease.
  • Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome.
  • The aim of this study was to assess the relationship between severity of liver injury and atherogenic lipid profile in a large group of children with NAFLD.
  • This study shows for the first time that in children with NAFLD, the severity of liver injury is strongly associated with the presence of a more atherogenic lipid profile, having potential significant diagnostic and therapeutic implications.
  • [MeSH-major] Atherosclerosis / diagnosis. Fatty Liver / diagnosis. Lipids / blood. Liver / pathology. Liver Cirrhosis / diagnosis

  • Genetic Alliance. consumer health - Liver Disease.
  • MedlinePlus Health Information. consumer health - Atherosclerosis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496475.001).
  • [ISSN] 1530-0447
  • [Journal-full-title] Pediatric research
  • [ISO-abbreviation] Pediatr. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Lipids
  •  go-up   go-down


80. Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F, Schwartz LH, Allen P, D'Angelica M, Fong Y, DeMatteo RP, Blumgart LH, Jarnagin WR: Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB (Oxford); 2009 Aug;11(5):445-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma.
  • BACKGROUND: In patients with hilar cholangiocarcinoma, ipsilateral en bloc hepatic resection improves survival but is associated with increased morbidity.
  • Preoperative biliary drainage of the future liver remnant (FLR) and contralateral portal vein embolization (PVE) may improve perioperative outcome, but their routine use is controversial.
  • This study analyses the impact of FLR volume and preoperative biliary drainage on postoperative hepatic insufficiency and mortality rates.
  • METHODS: Patients who underwent hepatic resection and for whom adequate imaging data for FLR calculation were available were identified retrospectively.
  • The volume of the FLR was calculated based on the total liver volume and the volume of the resection that was actually performed using semi-automated contouring of the liver on preoperative helical acquired scans.
  • Hepatic insufficiency was defined as a postoperative rise in bilirubin of 5 mg/dl above the preoperative level that persisted for >5 days postoperatively.
  • RESULTS: Sixty patients were identified who underwent hepatic resection between 1997 and 2007 and for whom imaging data were available for analysis.
  • Preoperative FLR volume was a predictor of hepatic insufficiency and death (P= 0.03).
  • No patient in this group had hepatic insufficiency, but there were two operative deaths (5%), both occurring in patients who underwent preoperative biliary drainage.
  • By contrast, in the group with FLR < 30% (21/60, 35%), hepatic insufficiency was seen in five patients and operative mortality in four patients, and were strongly associated with lack of preoperative biliary drainage of the FLR (P = 0.009).
  • CONCLUSIONS: In patients undergoing liver resection for hilar cholangiocarcinoma, FLR volume of < 30% of total liver volume is associated with increased risk for hepatic insufficiency and death.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] HPB (Oxford). 2008;10(2):126-9 [18773089.001]
  • [Cites] Ann Surg. 1999 Nov;230(5):663-71 [10561090.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(5):441-6 [17909711.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1488-94 [17048280.001]
  • [Cites] Ann Surg. 2006 Aug;244(2):240-7 [16858186.001]
  • [Cites] World J Gastroenterol. 2005 Nov 28;11(44):7024-7 [16437610.001]
  • [Cites] Ann Surg. 2005 May;241(5):703-12; discussion 712-4 [15849506.001]
  • [Cites] Ann Surg. 2005 May;241(5):693-9; discussion 699-702 [15849505.001]
  • [Cites] Surgery. 2005 Feb;137(2):148-55 [15674194.001]
  • [Cites] Arch Surg. 1999 Mar;134(3):261-6 [10088565.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):385-94 [9742921.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):947-54 [9060532.001]
  • [Cites] Am J Surg. 1996 Feb;171(2):230-4 [8619456.001]
  • [Cites] Br J Surg. 1994 Aug;81(8):1195-8 [7741850.001]
  • [Cites] HPB Surg. 1994;8(1):27-31 [7993861.001]
  • [Cites] Ann Surg. 1985 May;201(5):545-53 [2986562.001]
  • [Cites] Surg Clin North Am. 1989 Apr;69(2):323-37 [2538936.001]
  • [Cites] J Surg Res. 1986 Aug;41(2):113-25 [3762122.001]
  • [Cites] Surgery. 1985 Jun;97(6):641-8 [3890241.001]
  • [Cites] Surgery. 1990 Aug;108(2):370-4; discussion 374-5 [2200158.001]
  • [Cites] Lancet. 1982 Oct 23;2(8304):896-9 [6126752.001]
  • [Cites] Br J Surg. 1984 May;71(5):371-5 [6372935.001]
  • [Cites] Ann Surg. 2004 Jul;240(1):95-101 [15213624.001]
  • [Cites] Arch Surg. 2004 May;139(5):514-23; discussion 523-5 [15136352.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):84-92 [12832969.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):73-83 [12832968.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):325-30 [12654556.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):803-13 [12035036.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):507-17; discussion 517-9 [11573044.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):155-62 [10982608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):148-54 [10982607.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):135-41 [10982605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2000;7(2):128-34 [10982604.001]
  • [Cites] Ann Surg. 2000 Aug;232(2):166-74 [10903592.001]
  • [Cites] Surgery. 2000 Apr;127(4):395-404 [10776430.001]
  • [Cites] Arch Surg. 2000 Mar;135(3):302-8 [10722032.001]
  • [Cites] Ann Surg. 1999 Dec;230(6):808-18; discussion 819 [10615936.001]
  • [Cites] J Am Coll Surg. 1999 Dec;189(6):575-83 [10589594.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2008;15(1):25-30 [18274841.001]
  • (PMID = 19768150.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2742615
  • [Keywords] NOTNLM ; biliary drainage / hilar cholangiocarcinoma / jaundice / klatskin tumor
  •  go-up   go-down


81. Salles VJ, Marotta A, Netto JM, Speranzini MB, Martins MR: Bile duct hamartomas--the von Meyenburg complex. Hepatobiliary Pancreat Dis Int; 2007 Feb;6(1):108-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hamartomas of the bile duct (von Meyenburg complex) are benign neoplasms of the liver, constituted histologically cystic dilatations of the bile duct, encompassed by fibrous stroma.
  • We report a 42-year-old female patient with symptomatic cholecystitis, whose gross and ultrasonic appearance suggestive of multiple liver metastases.
  • Magnetic resonance imaging and liver biopsy are the gold standards for diagnosis of this rare hepatobiliary condition.

  • MedlinePlus Health Information. consumer health - Bile Duct Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17287178.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  •  go-up   go-down


82. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL: Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut; 2010 Jul;59(7):969-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years.
  • BACKGROUND: Patients with non-alcoholic steatohepatitis (NASH) have increased mortality and liver-related complications.
  • In contrast, simple steatosis is considered benign and non-progressive.
  • OBJECTIVE: To investigate disease progression in patients with different degrees of non-alcoholic fatty liver disease (NAFLD) activity.
  • PATIENTS: Fifty-two patients (age 44+/-9 years) with biopsy-proven NAFLD had liver biopsies repeated at month 36.
  • RESULTS: Among 13 patients with simple steatosis at baseline, 2 (15%) had a normal liver at month 36, 3 (23%) continued to have simple steatosis, 5 (39%) developed borderline NASH and 3 (23%) developed NASH.
  • The baseline serum levels and month 36 changes in adiponectin, tumour necrosis factor alpha, interleukin 6 and leptin were not associated with disease progression.
  • [MeSH-major] Fatty Liver / pathology. Liver / pathology


83. Aberg F, Jula A, Höckerstedt K, Isoniemi H: Cardiovascular risk profile of patients with acute liver failure after liver transplantation when compared with the general population. Transplantation; 2010 Jan 15;89(1):61-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular risk profile of patients with acute liver failure after liver transplantation when compared with the general population.
  • BACKGROUND: As opposed to most solid-organ transplant recipients, patients with acute liver failure exhibit a pretransplant health status more comparable with the general population, and any posttransplant cardiovascular risk excess should thus be more attributable to transplantation-related factors alone.
  • METHODS: This study compared the cardiovascular risk of 77 consecutive patients with acute liver failure at 5 years after liver transplantation with that of the general population using age, sex, and residence area-standardized prevalence ratios (SPR).
  • CONCLUSIONS: Liver transplantation and associated immunosuppression evidently cause hypertension, and possibly elicit diabetes in susceptible individuals.
  • [MeSH-major] Cardiovascular Diseases / epidemiology. Liver Failure, Acute / complications. Liver Failure, Acute / etiology. Liver Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061920.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Lipids
  •  go-up   go-down


84. Fan ST: Live donor liver transplantation in adults. Transplantation; 2006 Sep 27;82(6):723-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Live donor liver transplantation in adults.
  • Live donor liver transplantation (LDLT) was initiated in 1988 for children recipients.
  • Its application to adult recipients was limited by graft size until the first right liver LDLT was performed in Hong Kong in 1996.
  • Since then, right liver graft has become the major graft type.
  • The need for routine liver biopsy in donor evaluation is arguable but more and more centers opt for a policy of liberal liver biopsy.
  • Donation of the middle hepatic vein (MHV) in the right liver graft was considered unsafe but now data indicate that the outcome of donors with or without MHV donation is about equal.
  • Right liver LDLT has been shown to improve the overall survival rate of patients with chronic liver disease, acute or acute-on-chronic liver failure and hepatocellular carcinoma waiting for liver transplantation.
  • The outcome of LDLT is equivalent to deceased donor liver transplantation despite a smaller graft size and higher technical complexity.
  • [MeSH-major] Liver Transplantation. Living Donors
  • [MeSH-minor] Adult. Child. Hepatectomy / methods. Humans. Liver / anatomy & histology. Patient Selection. Tissue and Organ Harvesting / methods


85. Fernández-Real JM, Ortega F, Gómez-Ambrosi J, Salvador J, Frühbeck G, Ricart W: Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int; 2010 Dec;21(12):2101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss.
  • SUMMARY: The expression of liver genes was associated with insulin action in osteocalcin knockout mice.
  • Our findings suggest that osteocalcin may play a role in the development of insulin resistance-associated fatty liver disease.
  • INTRODUCTION: The expression of insulin target genes was decreased in the liver of mice lacking osteocalcin.
  • We aimed to explore the association of liver enzymes with osteocalcin.
  • CONCLUSIONS: In summary, our findings suggest a bone-liver axis in which osteocalcin might be the active regulator.
  • [MeSH-major] Fatty Liver / blood. Osteocalcin / blood. Weight Loss / physiology

  • MedlinePlus Health Information. consumer health - Weight Control.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thromb Haemost. 2006 Jun;95(6):991-6 [16732378.001]
  • [Cites] Am J Med. 2003 Nov;115(7):554-9 [14599635.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1103-9 [7523217.001]
  • [Cites] Diabetes Care. 2006 May;29(5):1058-64 [16644637.001]
  • [Cites] Clin Biochem. 2002 Jun;35(4):315-20 [12135695.001]
  • [Cites] Hepatology. 1995 Feb;21(2):389-92 [7843710.001]
  • [Cites] Cell. 2007 Aug 10;130(3):456-69 [17693256.001]
  • [Cites] J Autism Dev Disord. 2008 May;38(5):848-56 [17879151.001]
  • [Cites] Obesity (Silver Spring). 2008 Jun;16(6):1355-62 [18421281.001]
  • [Cites] Semin Liver Dis. 2001;21(1):81-8 [11296699.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Gastroenterology. 2007 Aug;133(2):608-18 [17681180.001]
  • [Cites] Ann Intern Med. 1985 Dec;103(6 ( Pt 1)):855-60 [4062087.001]
  • [Cites] Cell. 2008 Nov 28;135(5):825-37 [19041748.001]
  • [Cites] Obes Surg. 2008 Sep;18(9):1134-43 [18563500.001]
  • [Cites] Hum Pathol. 1989 Jun;20(6):594-8 [2656500.001]
  • [Cites] J Hepatol. 1991 Mar;12(2):224-9 [2051001.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):237-45 [18854399.001]
  • [Cites] Hepatology. 1999 Mar;29(3):664-9 [10051466.001]
  • [Cites] Int J Obes Relat Metab Disord. 1998 Mar;22(3):222-6 [9539189.001]
  • [Cites] Am J Med Sci. 2005 Dec;330(6):326-35 [16355018.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Diabetes. 2006 Jan;55(1):216-24 [16380496.001]
  • [Cites] Am J Clin Nutr. 2008 May;87(5):1141-7 [18469232.001]
  • [Cites] Gastroenterology. 1989 Jan;96(1):213-21 [2783312.001]
  • [Cites] Hepatology. 1991 Aug;14 (2):257-61 [1860683.001]
  • [Cites] Hepatology. 2000 Jul;32(1):3-10 [10869282.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • (PMID = 20204603.001).
  • [ISSN] 1433-2965
  • [Journal-full-title] Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  • [ISO-abbreviation] Osteoporos Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 104982-03-8 / Osteocalcin; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase
  •  go-up   go-down


86. Viganò L, Laurent A, Tayar C, Merle JC, Lauzet JY, Hurtova M, Decaens T, Duvoux C, Cherqui D: Outcomes in adult recipients of right-sided liver grafts in split-liver procedures. HPB (Oxford); 2010 Apr;12(3):195-203
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in adult recipients of right-sided liver grafts in split-liver procedures.
  • BACKGROUND: The split-liver technique provides a good left lateral graft in children, but its results in adults remain controversial.
  • Donors and recipients were selected for good quality grafts and elective indications; the latter included a high proportion of tumour cases and primary sclerosing cholangitis.
  • Grafts included 31 extended right grafts (ERGs; segments IV-VIII and I and the inferior vena cava [IVC]) and seven right grafts (RGs; segments V-VIII) including five without the IVC and middle hepatic vein (MHV).
  • CONCLUSIONS: Split-liver transplantation is a safe alternative to whole organ transplantation when an ERG is carried out.
  • Split-liver transplantation with an ERG offers excellent outcomes and should be encouraged when good quality grafts are available.
  • [MeSH-major] Graft Survival. Liver Transplantation / methods. Liver Transplantation / mortality

  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):283-9; discussion 289-90 [10693682.001]
  • [Cites] Transplantation. 2008 May 27;85(10):1420-4 [18497681.001]
  • [Cites] Ann Surg. 2001 Apr;233(4):565-74 [11303140.001]
  • [Cites] Transplantation. 2002 Mar 15;73(5):765-9 [11907425.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):241-7 [12170030.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):248-53 [12170031.001]
  • [Cites] J Am Coll Surg. 2002 Nov;195(5):648-57 [12437252.001]
  • [Cites] Ann Surg. 2003 Feb;237(2):180-5 [12560775.001]
  • [Cites] Transplantation. 2003 Apr 27;75(8):1197-203 [12717203.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):496-505; discussion 506-7 [14530721.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):172-81 [14745324.001]
  • [Cites] Am J Transplant. 2004 Nov;4(11):1792-7 [15476478.001]
  • [Cites] Langenbecks Arch Chir. 1988;373(2):127-30 [3287073.001]
  • [Cites] Br J Surg. 1989 Jul;76(7):722-4 [2670054.001]
  • [Cites] Surgery. 1990 Jun;107(6):605-12 [2353304.001]
  • [Cites] Ann Surg. 1990 Jul;212(1):14-22 [2363599.001]
  • [Cites] Ann Surg. 1990 Sep;212(3):368-75; discussion 375-7 [2396888.001]
  • [Cites] Br J Surg. 1993 Jan;80(1):75-80 [8428301.001]
  • [Cites] Transplantation. 1993 Nov;56(5):1130-6 [8249113.001]
  • [Cites] Transplantation. 1994 Oct 15;58(7):793-6 [7940712.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):331-9; discussion 339-41 [8813261.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):737-46; discussion 746-8 [8968228.001]
  • [Cites] Transplantation. 1997 Sep 27;64(6):871-7 [9326413.001]
  • [Cites] Ann Surg. 1998 Feb;227(2):282-8 [9488528.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):411-20 [9742924.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):802-12, discussion 812-3 [16327490.001]
  • [Cites] Lancet. 2006 Jan 21;367(9506):225-32 [16427491.001]
  • [Cites] Am J Transplant. 2006 Apr;6(4):783-90 [16539636.001]
  • [Cites] Liver Transpl. 2006 May;12(5):839-44 [16628692.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):865-72; discussion 872-3 [17122611.001]
  • [Cites] Liver Transpl. 2007 Jun;13(6):829-37 [17539013.001]
  • [Cites] Transpl Int. 2008 Mar;21(3):218-22 [17850237.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):312-23 [10973381.001]
  • (PMID = 20590887.001).
  • [ISSN] 1477-2574
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2889272
  •  go-up   go-down


87. Yin XM, Ding WX, Gao W: Autophagy in the liver. Hepatology; 2008 May;47(5):1773-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autophagy in the liver.
  • A great part of our current understanding of mammalian macroautophagy is derived from studies of the liver.
  • The term "autophagy" was introduced by Christian de Duve in part based on ultrastructural changes in rat liver following glucagon injection.
  • Subsequent morphological, biochemical, and kinetics studies of autophagy in the liver defined the basic process of autophagosome formation, maturation, and degradation and the regulation of autophagy by hormones, phosphoinositide 3-kinases, and mammalian target of rapamycin.
  • It is now clear that macroautophagy in the liver is important for the balance of energy and nutrients for basic cell functions, the removal of misfolded proteins resulting from genetic mutations or pathophysiological stimulations, and the turnover of major subcellular organelles such as mitochondria, endoplasmic reticulum, and peroxisomes under both normal and pathophysiological conditions.
  • Disturbance of autophagy function in the liver could thus have a major impact on liver physiology and liver disease.
  • [MeSH-major] Autophagy / physiology. Liver / cytology. Liver / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18393362.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA111456; United States / NCI NIH HHS / CA / CA83817
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 115
  •  go-up   go-down


88. Piemonte F, Petrini S, Gaeta LM, Tozzi G, Bertini E, Devito R, Boldrini R, Marcellini M, Ciacco E, Nobili V: Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 2):e457-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Protein glutathionylation increases in the liver of patients with non-alcoholic fatty liver disease.
  • In this study, we analyzed the protein glutathionylation in non-alcoholic fatty liver disease (NAFLD) and evaluated a potential association between glutathionylation, fibrosis, and vitamin E treatment.
  • METHODS: Protein glutathionylation was studied in the livers of 36 children (mean age 12.5 years, range 4-16 years) subdivided into three groups according to their NAFLD activity score (NAS) by Western blot analysis and immunohistochemistry, using a specific monoclonal antibody.
  • RESULTS: Our findings showed that protein glutathionylation increases in the livers of patients with NAFLD and it is correlated with steatohepatitis and liver fibrosis.
  • CONCLUSION: Protein glutathionylation significantly increases in livers with NAFLD, strongly suggesting that oxidative injury plays a crucial role in this disease.
  • Furthermore, the marked increase of protein glutathionylation, in correlation with collagen VI immunoreactivity, suggests a link between the redox status of hepatic protein thiols and fibrosis.
  • [MeSH-major] Fatty Liver / metabolism. Glutathione / metabolism. Liver / metabolism. Oxidative Stress. Proteins / metabolism
  • [MeSH-minor] Adolescent. Antioxidants / therapeutic use. Child. Child, Preschool. Collagen Type VI / metabolism. Female. Hepatocytes / metabolism. Humans. Liver Cirrhosis / metabolism. Liver Cirrhosis / physiopathology. Liver Cirrhosis / therapy. Male. Vitamin E / therapeutic use

  • Genetic Alliance. consumer health - Liver Disease.
  • Genetic Alliance. consumer health - Non-alcoholic steatohepatitis (NASH).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17683488.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Collagen Type VI; 0 / Proteins; 1406-18-4 / Vitamin E; GAN16C9B8O / Glutathione
  •  go-up   go-down


89. Del Gaudio M, Ercolani G, Ravaioli M, Cescon M, Lauro A, Vivarelli M, Zanello M, Cucchetti A, Vetrone G, Tuci F, Ramacciato G, Grazi GL, Pinna AD: Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant; 2008 Jun;8(6):1177-85
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience.
  • Liver resection (LR) for patients with small hepatocellular carcinoma (HCC) with preserved liver function, employing liver transplantation (LT) as a salvage procedure (SLT) in the event of HCC recurrence, is a debated strategy.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Liver Neoplasms / surgery. Liver Transplantation. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Aged. Female. Hepatectomy. Humans. Italy. Liver Cirrhosis / complications. Male. Middle Aged. Salvage Therapy


90. Brigman C, Feranchak A: Liver involvement in cystic fibrosis. Curr Treat Options Gastroenterol; 2006;9(6):484-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver involvement in cystic fibrosis.
  • The factor(s) responsible for the development and progression of liver disease in a subset of patients with CF are unknown.
  • Liver disease can be silent and progressive, manifesting only with complications associated with cirrhosis and portal hypertension.
  • Clinical evaluation for detecting and monitoring the progression of liver disease includes the following: physical examination of the liver, biochemical tests of liver function and injury, and radiological imaging with abdominal ultrasonography.
  • Careful monitoring should take place in all patients with CF, as currently, there are no sensitive and/or specific historical or biochemical markers to predict who is at risk for the development of liver disease.
  • Current treatment options for CF-associated liver disease are very limited.
  • The bile acid ursodeoxycholic acid may improve biochemical parameters of liver disease, but its long-term efficacy in preventing the progression of liver disease in CF is unproven.
  • Treatment therefore rests on optimizing nutritional status; correcting fat-soluble vitamin, essential fatty acid, and other mineral deficiencies; and treating complications of end-stage liver disease, such as pruritus, ascites, and portal hypertension.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 1999 Nov;135(5):601-10 [10547249.001]
  • [Cites] AJR Am J Roentgenol. 1992 Dec;159(6):1277-8 [1442401.001]
  • [Cites] Hepatology. 1992 Apr;15(4):677-84 [1551646.001]
  • [Cites] Science. 1989 Sep 8;245(4922):1066-73 [2475911.001]
  • [Cites] N Engl J Med. 1997 May 1;336(18):1283-9 [9113931.001]
  • [Cites] Hepatology. 1996 Jun;23(6):1484-90 [8675168.001]
  • [Cites] Pediatr Radiol. 1997 Jul;27(7):588-90 [9211953.001]
  • [Cites] Ann Intern Med. 1995 Aug 15;123(4):280-7 [7611595.001]
  • [Cites] World J Surg. 1985 Apr;9(2):258-68 [3993057.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999 Oct;29(4):442-7 [10512405.001]
  • [Cites] JPEN J Parenter Enteral Nutr. 1992 Mar-Apr;16(2):106-9 [1556803.001]
  • [Cites] Transpl Int. 1997;10(1):33-9 [9002149.001]
  • [Cites] Pediatr Transplant. 2003 Apr;7(2):93-7 [12654048.001]
  • [Cites] Hepatology. 1995 Apr;21(4):963-9 [7535738.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2002 Sep;35(3):246-59 [12352509.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1995 Feb;20(2):202-8 [7714687.001]
  • [Cites] Hepatology. 2004 Sep;40(3):693-8 [15349909.001]
  • [Cites] Thorax. 2001 Oct;56(10):746-50 [11562511.001]
  • [Cites] Clin Radiol. 2000 Mar;55(3):236-7 [10708619.001]
  • [Cites] Hepatology. 2002 Jul;36(1):49-54 [12085348.001]
  • [Cites] Liver. 1998 Apr;18(2):73-89 [9588766.001]
  • [Cites] Hepatology. 1990 May;11(5):884-7 [2161397.001]
  • [Cites] N Engl J Med. 1995 Aug 31;333(9):555-60 [7623904.001]
  • [Cites] Hepatology. 2002 Dec;36(6):1374-82 [12447862.001]
  • [Cites] Gastroenterology. 1996 Jul;111(1):165-71 [8698195.001]
  • [Cites] Gastrointest Endosc. 1989 Sep-Oct;35(5):377-80 [2792671.001]
  • [Cites] Arch Dermatol. 1985 Nov;121(11):1415-20 [3901929.001]
  • [Cites] Nutrition. 2000 Jul-Aug;16(7-8):566-70 [10906558.001]
  • [Cites] Annu Rev Nutr. 1993;13:111-36 [8369141.001]
  • [Cites] Stat Med. 1996 Mar 15;15(5):449-62 [8668871.001]
  • [Cites] J Pediatr Surg. 2003 Aug;38(8):1152-6 [12891484.001]
  • [Cites] J Pediatr. 1995 Nov;127(5):681-4 [7472816.001]
  • [Cites] Hepatology. 1992 Oct;16(4):924-30 [1398498.001]
  • [Cites] Hepatogastroenterology. 2003 Jul-Aug;50(52):1111-4 [12845992.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1999;28 Suppl 1:S1-13 [9934970.001]
  • [Cites] Lancet. 1990 May 5;335(8697):1098 [1970397.001]
  • [Cites] J Immunol. 1996 Feb 15;156(4):1601-8 [8568266.001]
  • [Cites] Nat Clin Pract Gastroenterol Hepatol. 2006 Jun;3(6):318-28 [16741551.001]
  • [Cites] Transpl Int. 2005 Feb;18(2):246-55 [15691279.001]
  • [Cites] Circulation. 1994 Apr;89(4):1530-8 [8149518.001]
  • [Cites] Hepatology. 1998 Jan;27(1):166-74 [9425933.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1857-64 [7504645.001]
  • [Cites] J Pediatr. 1985 Feb;106(2):317-21 [3968624.001]
  • [Cites] Arch Dis Child. 1999 Aug;81(2):129-32 [10490519.001]
  • [Cites] Curr Opin Pulm Med. 2002 Nov;8(6):542-6 [12394164.001]
  • [Cites] J Pediatr. 2004 Sep;145(3):322-6 [15343184.001]
  • [Cites] J R Soc Med. 1986;79 Suppl 12:55-63 [3522917.001]
  • [Cites] Arch Dis Child. 1997 Dec;77(6):476-7 [9496177.001]
  • [Cites] Br J Surg. 1988 May;75(5):404-8 [3390666.001]
  • [Cites] Hepatology. 1994 Oct;20(4 Pt 1):1092-5 [7927213.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):170-83 [11438506.001]
  • [Cites] Hepatology. 2005 Oct;42(4):782-92 [16175620.001]
  • [Cites] Arch Dis Child. 1997 Dec;77(6):493-6 [9496181.001]
  • [Cites] Hepatology. 1999 Nov;30(5):1151-8 [10534335.001]
  • [Cites] Am J Clin Nutr. 1992 Jan;55(1):108-16 [1728810.001]
  • [Cites] Gastroenterol Clin North Am. 2000 Jun;29(2):387-421, vi [10836187.001]
  • (PMID = 17081482.001).
  • [ISSN] 1092-8472
  • [Journal-full-title] Current treatment options in gastroenterology
  • [ISO-abbreviation] Curr Treat Options Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Jakobsen MU, Berentzen T, Sørensen TI, Overvad K: Abdominal obesity and fatty liver. Epidemiol Rev; 2007;29:77-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal obesity and fatty liver.
  • It has been hypothesized that visceral fat releases free fatty acids and adipokines and thereby exposes the liver to fat accumulation.
  • The authors aimed to evaluate current epidemiologic evidence for an association between abdominal fat and liver fat content.
  • Clinical and epidemiologic studies with data on abdominal fat and liver fat content were reviewed.
  • Studies using waist circumference to estimate abdominal fat mass suggested a direct association between abdominal fat and liver fat content.
  • Studies using imaging methods suggested a direct association between intraabdominal fat and liver fat content, but not between subcutaneous abdominal fat and liver fat content.
  • In conclusion, clinical and epidemiologic studies of abdominal fat and liver fat content suggest a direct association between abdominal fat and liver fat content which is probably accounted for by visceral fat.
  • Both abdominal fat depots and other body compartments of interest should be included to further investigate the association between specific fat depots and liver fat content.
  • [MeSH-major] Abdominal Fat / metabolism. Fatty Liver / metabolism. Obesity / metabolism

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17478441.001).
  • [ISSN] 0193-936X
  • [Journal-full-title] Epidemiologic reviews
  • [ISO-abbreviation] Epidemiol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 37
  •  go-up   go-down


92. Gassanov N, Caglayan E, Erdmann E, Er F: [Amiodarone-induced liver dysfunctions]. Dtsch Med Wochenschr; 2010 Jul;135(27):1372-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Amiodarone-induced liver dysfunctions].
  • Amiodarone is highly lipophilic and accumulation in the liver can be 500 times higher than serum amiodarone levels.
  • Due to a long half-life and the lipophilic properties, the stored drug is capable of damaging the liver long after the drug has been stopped.
  • Serious liver damage can lead to acute liver failure, cirrhosis and the need for liver transplantation.
  • In this article we describe amiodarone-induced liver dysfunction and the diagnostic and therapeutic challenges in patients on amiodarone.
  • [MeSH-major] Amiodarone / adverse effects. Anti-Arrhythmia Agents / adverse effects. Atrial Fibrillation / drug therapy. Drug-Induced Liver Injury / etiology. Liver Function Tests

  • MedlinePlus Health Information. consumer health - Atrial Fibrillation.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 20589584.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; EC 2.6.1.1 / Aspartate Aminotransferases; EC 2.6.1.2 / Alanine Transaminase; N3RQ532IUT / Amiodarone
  •  go-up   go-down


93. Krawczyk M, Bonfrate L, Portincasa P: Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol; 2010 Oct;24(5):695-708
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonalcoholic fatty liver disease.
  • Non-alcoholic fatty liver disease (NAFLD), the most common liver disorder in the Western world, is a clinico-histopathological entity in which excessive triglyceride accumulation in the liver occurs.
  • Non-alcoholic steatohepatitis (NASH) represents the necroinflammatory form, which can lead to advanced liver fibrosis, cirrhosis, and hepatocellular carcinoma.
  • The pathogenesis of NAFLD/NASH is complex but increased visceral adiposity plus insulin resistance with increased free fatty acids release play an initial key role for the onset and perpetuation of liver steatosis.
  • Further events in the liver include oxidative stress and lipid peroxidation, decreased antioxidant defences, early mitochondrial dysfunction, iron accumulation, unbalance of adipose-derived adipokines with a chronic proinflammatory status, and gut-derived microbial adducts.
  • New gene polymorphisms increasing the risk of fatty liver, namely APOC3 and PNPLA3, have been lately identified allowing further insights into the pathogenesis of this condition.
  • [MeSH-major] Fatty Liver
  • [MeSH-minor] Abdominal Fat. Animals. Body Mass Index. Disease Progression. Genome-Wide Association Study. Humans. Insulin Resistance. Liver / pathology. Liver / physiopathology. Liver Cirrhosis / physiopathology. Liver Function Tests. Membrane Proteins / genetics. Metabolic Syndrome X / diagnosis. Non-alcoholic Fatty Liver Disease. Obesity, Abdominal / epidemiology. Obesity, Abdominal / physiopathology. Oxidative Stress / physiology. Polymorphism, Single Nucleotide. Risk Factors. Sleep Apnea Syndromes / epidemiology. Triglycerides / blood

  • Genetic Alliance. consumer health - Liver Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20955971.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Triglycerides; 0 / adiponutrin
  •  go-up   go-down


94. Maillette de Buy Wenniger L, Terpstra V, Beuers U: Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology. Dig Surg; 2010;27(1):24-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Focal nodular hyperplasia and hepatic adenoma: epidemiology and pathology.
  • Focal nodular hyperplasia (FNH) and hepatic adenoma (HA) represent the most frequent non-vascular benign liver tumors.
  • FNH is the most common non-vascular benign tumor of the liver.
  • HA is a rare monoclonal, but benign liver tumor primarily found in young females using estrogen-containing contraceptives.
  • Withdrawal of estrogen treatment and excision of large tumors (>5 cm) are established therapeutic strategies.
  • [MeSH-major] Focal Nodular Hyperplasia / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20357448.001).
  • [ISSN] 1421-9883
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


95. Nadalin S, Malagó M, Valentin-Gamazo C, Testa G, Baba HA, Liu C, Frühauf NR, Schaffer R, Gerken G, Frilling A, Broelsch CE: Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl; 2005 Aug;11(8):980-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits.
  • The role of liver biopsy (LB) in donor selection for adult living donor liver transplantation remains controversial, since the procedure is associated with additional potential risks for the donor.
  • Thirty-one (21%) of 144 candidates who underwent an LB had a positive finding at histological examination that induced their exclusion from donation, of whom 21 had liver steatosis of varying kind and grade (10%-80%) and 10 had a nonsteatotic hepatopathy (non-A-D hepatitis in 6 cases, diffuse granulomatosis in 2, schistosomiasis in 1, fibrosis in 1).
  • [MeSH-major] Biopsy, Needle / adverse effects. Liver / pathology. Liver Transplantation. Living Donors. Preoperative Care
  • [MeSH-minor] Adult. Fatty Liver / pathology. Female. Hematoma / etiology. Humans. Liver Diseases / etiology. Liver Diseases / pathology. Male. Middle Aged. Patient Selection. Risk Assessment

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035060.001).
  • [ISSN] 1527-6465
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Hidalgo A, Tabernero J, Rojo F, Marimon I, Andreu J, Baselga J: Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs. Abdom Imaging; 2005 Jan-Feb;30(1):65-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of CT scan-guided Tru-Cut serial liver biopsies to evaluate pharmacodynamic endpoints in patients with liver metastasis treated with experimental drugs.
  • We assessed the feasibility of using computed tomographically guided, Tru-Cut serial liver biopsies to perform pharmacodynamic studies in patients with liver metastasis who had been treated with experimental drugs.
  • Twenty-three patients with liver metastasis were enrolled in two protocols for evaluation of the response to two new biologic drugs: a farnesyltransferase inhibitor and a tyrosine kinase inhibitor of the epidermal growth factor receptor.
  • We obtained 271 samples (168 from metastatic lesions and 103 from surrounding normal liver tissue) from 23 patients.
  • We found serial liver biopsies using Tru-Cut to be a safe and easy procedure.
  • [MeSH-major] Alkyl and Aryl Transferases / antagonists & inhibitors. Liver Neoplasms / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15647873.001).
  • [ISSN] 0942-8925
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


97. Lin YC, Hsiao ST, Chen JD: Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults. World J Gastroenterol; 2007 Mar 28;13(12):1805-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.
  • AIM: To examine the epidemiology of hepatitis B virus carrier status (HBVC) and sonographic fatty liver (SFL) in Taiwanese adults, and to evaluate their possible interaction in inducing liver damage (LD).
  • >From an epidemiological viewpoint, we analyzed previous studies which indicated that fatty liver sensitizes host immune response to HBV infection and enhances liver damage.
  • METHODS: A cross-sectional retrospective analysis of health records including medical history, physical examination, abdominal sonogram, blood biochemistry and hepatic virological tests.
  • [MeSH-major] Carrier State / pathology. Fatty Liver / complications. Hepatitis B / complications. Hepatitis B virus. Liver Diseases / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Alanine Transaminase / blood. Cross-Sectional Studies. Female. Health Surveys. Hepatitis B Vaccines / therapeutic use. Humans. Liver / metabolism. Liver / pathology. Liver / virology. Logistic Models. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Taiwan / epidemiology

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17465470.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines; EC 2.6.1.2 / Alanine Transaminase
  • [Other-IDs] NLM/ PMC4149956
  •  go-up   go-down


98. Kubota H, Yao HL, Reid LM: Identification and characterization of vitamin A-storing cells in fetal liver: implications for functional importance of hepatic stellate cells in liver development and hematopoiesis. Stem Cells; 2007 Sep;25(9):2339-49
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of vitamin A-storing cells in fetal liver: implications for functional importance of hepatic stellate cells in liver development and hematopoiesis.
  • Hepatic stellate cells (HpSTCs) are major regulators of hepatic fibrogenesis in adults.
  • However, their early development in fetal liver is largely unknown.
  • To characterize fetal HpSTCs in the liver, in which hepatic development and hematopoiesis occur in parallel, we determined the phenotypic characteristics of HpSTCs from rat fetal livers, using a strategy focused on vitamin A.
  • A characteristic vA+ cell population was identified in liver as early as 13 days post coitum; it had a surface phenotype of RT1A- intercellular adhesion molecule (ICAM)-1+ vascular cell adhesion molecule (VCAM)-1+ beta3-integrin+.
  • Although nonspecific autofluorescent cells were found with the antigenic profile of RT1A- ICAM-1+ VCAM-1+, they were beta3-integrin- and proved to be hepatoblasts, bipotent hepatic parenchymal progenitors.
  • Furthermore, the vA+ cells strongly express hepatocyte growth factor, stromal-derived factor-1alpha, and Hlx (homeobox transcription factor), indicating that they play important roles for hepatic development and hematopoiesis.
  • The abilities to isolate and expand fetal HpSTCs enable further investigation into their roles in early liver development and facilitate identification of possibly novel signals of potential relevance for liver diseases.
  • [MeSH-major] Hematopoiesis, Extramedullary / physiology. Liver / cytology. Liver / embryology. Organogenesis / physiology. Vitamin A / metabolism

  • MedlinePlus Health Information. consumer health - Vitamin A.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. VITAMIN A .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585172.001).
  • [ISSN] 1549-4918
  • [Journal-full-title] Stem cells (Dayton, Ohio)
  • [ISO-abbreviation] Stem Cells
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA014243; United States / NIDDK NIH HHS / DK / DK52851; United States / NIDDK NIH HHS / DK / IP30-DK065933
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Integrin beta3; 0 / Vascular Cell Adhesion Molecule-1; 0 / histocompatibility antigens RT, rat; 11103-57-4 / Vitamin A
  •  go-up   go-down


99. Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, Yong BH, Chiu A, Lam BK: Liver transplantation for acute-on-chronic liver failure. Hepatol Int; 2009 Dec;3(4):571-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation for acute-on-chronic liver failure.
  • PURPOSE: To evaluate the outcome of liver transplantation for acute-on-chronic liver failure.
  • PATIENTS AND METHODS: From November 1991 to December 2007, 517 patients underwent liver transplantation at Queen Mary Hospital, Hong Kong.
  • Among them, 149 had acute-on-chronic liver failure as defined in the recent Asian Pacific Association for the Study of Liver Consensus Meeting.
  • Their clinical data were reviewed and their survival outcomes were compared with those of patients who underwent liver transplantation for fulminant hepatic failure and for cirrhosis only in the same period.
  • RESULTS: The patients with acute-on-chronic liver failure included 50 patients having acute exacerbation of chronic hepatitis B and 99 cirrhotic patients with acute deterioration.
  • Their median model for end-stage liver disease scores were 35 and 37, respectively.
  • One hundred and three patients received living donor liver grafts and 46 patients received deceased donor liver grafts.
  • The results were similar to those of the patients with fulminant hepatic failure (n = 37) and the patients having cirrhosis only (n = 301).
  • CONCLUSIONS: Liver transplantation for acute-on-chronic liver failure is life-saving, and the survival rates it attains are similar to those attained by transplantation for other liver conditions.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 2003 Jan;90(1):48-56 [12520574.001]
  • [Cites] Transplant Proc. 2008 Oct;40(8):2492-3 [18929776.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):979-84 [12684909.001]
  • [Cites] Liver Transpl. 2003 Jun;9(6):575-80 [12783398.001]
  • [Cites] Gastroenterology. 1989 Aug;97(2):439-45 [2490426.001]
  • [Cites] Hepatology. 1996 Jan;23(1):164-76 [8550036.001]
  • [Cites] Liver Transpl. 2000 May;6(3):296-301 [10827229.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):949-58 [12297843.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):137-48 [12832976.001]
  • [Cites] Liver Transpl. 2004 Jun;10(6):728-33 [15162466.001]
  • [Cites] Liver Transpl. 2007 Apr;13(4):509-15 [17394148.001]
  • [Cites] Hepatol Int. 2009 Mar;3(1):269-82 [19669378.001]
  • [Cites] Liver Int. 2006 Aug;26(6):695-702 [16842326.001]
  • [Cites] World J Surg. 2003 Mar;27(3):356-64 [12607066.001]
  • (PMID = 19680733.001).
  • [ISSN] 1936-0541
  • [Journal-full-title] Hepatology international
  • [ISO-abbreviation] Hepatol Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2790588
  •  go-up   go-down


100. Tsuchiya M, Otsuka Y, Tamura A, Nitta H, Sasaki A, Wakabayashi G, Kaneko H: Status of endoscopic liver surgery in Japan: a questionnaire survey conducted by the Japanese Endoscopic Liver Surgery Study Group. J Hepatobiliary Pancreat Surg; 2009;16(4):405-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Status of endoscopic liver surgery in Japan: a questionnaire survey conducted by the Japanese Endoscopic Liver Surgery Study Group.
  • BACKGROUND/PURPOSE: In 2007, the First Annual Meeting of the Japanese Endoscopic Liver Surgery Study Group was convened.
  • We report the results of a questionnaire survey conducted by this study group that attempted to assess the current status and safety of endoscopic liver surgery.
  • The rate of complications was 12.3%; there was no case of serious liver failure or operative mortality.
  • CONCLUSIONS: In properly selected patients, laparoscopic hepatectomy and endoscopic ablation therapy are safe treatments for liver tumors.
  • [MeSH-major] Catheter Ablation. Hepatectomy. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19458895.001).
  • [ISSN] 1436-0691
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Japan
  •  go-up   go-down






Advertisement